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This dissertation aims to investigate optical coherence tomography (OCT) as a 
diagnostic technology in renal imaging through two main arenas: renal transplantation 
and renal cancer. 
Part 1: Ischemia-reperfusion injury, which frequently occurs after kidney 
transplant, is a major contributing factor in delayed-graft function leading to varying 
degrees of early renal dysfunction. Real-time assessment of graft morphological and 
hemodynamic changes could help to evaluate graft condition and offer valuable 
information to predict the prognosis of graft injury for patient-specific management 
strategies. Previous studies have shown the ability of OCT to monitor structural changes 
associated with ischemia-reperfusion injury in vivo. Therefore, we investigated the ability 
of Doppler OCT (DOCT) to image microcirculatory changes in real time in the kidney 
glomerulus in vivo in an animal model and quantified observed changes in blood flow in 
3D. Then, we translated OCT/DOCT technology into clinical testing for renal imaging 
  
during transplantation procedures and demonstrated the ability of OCT/DOCT to reveal 
renal tubular morphology and blood flow immediately following reperfusion. 
Part 2: For solid renal masses, nephron sparing procedures have been developed 
as an alternative to radical nephrectomy. However, achieving a negative tumor margin is 
critical to ensuring the best oncological efficacy for precluding tumor recurrence. OCT is 
a high-resolution, real-time imaging technology that has shown the ability to distinguish 
cancerous tissue from normal in several systems of the body based on changes in tissue 
optical properties. Therefore, we investigated the capability of OCT to quantify 
differences in optical properties between tumor and normal renal tissue. However, we did 
not observe a significant difference in optical attenuation between tumor and normal 
tissue in ex vivo specimens. These results suggest that further studies or possible 
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Optical coherence tomography (OCT) is a high-resolution optical imaging 
modality that holds much promise for clinical medicine as it is capable of acquiring 
micrometer level images of the biological tissue subsurface. The interest in OCT as a 
diagnostic medical imaging tool has exploded over the past decade due to the 
performance and versatility of its application, and its capacity is constantly being 
transformed because of the technological advances with light sources, detectors, and 
processing algorithms. These attributes have pushed OCT into the spotlight for bed-side 
use in the clinic for diagnostic imaging. OCT is able to measure the optical properties of 
tissue and retrieve structural information (backscattered light intensity) as well as 
characterization and state of biological tissue (attenuation coefficient, phase, polarization, 
and other optical properties). Altogether, OCT has become a powerful tool for medical 
imaging. The scope of the research in this dissertation consists of three parts which 
investigate the utility and feasibility of OCT in renal imaging. The first section 
demonstrates OCT and Doppler OCT (DOCT) quantitative imaging in the living rat 
kidney; then, the second section translates that technique into the clinic to demonstrate 
real-time OCT/DOCT imaging of the living human kidney during renal transplantation; 
finally, the last section investigates the ability of OCT to distinguish between cancerous 
and normal renal tissue in human renal cancer patient specimens (ex vivo) by evaluating 
the differences in their optical properties. This opening chapter serves to introduce OCT 
and its place in the field of biomedical optics and provide a foundation upon which to 




In a broad sense, biomedical optics is a field that deals with the application of 
light in the ultraviolet-visible-infrared regions of the electromagnetic spectrum for 
diagnostic and therapeutic purposes. The field has evolved rapidly since the first reported 
study of laser technology in the 1960 by Maiman.
1
 Diagnostic applications primarily 
include imaging and spectroscopy, and for therapeutic applications, various forms of 
light-based therapy have been introduced and many have already been incorporated into 
common clinical practice. Also, the nature of the physical interaction between light and 
biological tissue is an important area of study in this field. 
Lasers have become a standard tool in clinics for several applications, the largest 
consisting of medical laser surgery and treatment. The application of lasers in medicine 
can be broken down in to approximately five categories based on the fluence rate of the 
laser light applied to biological tissue. On the higher end of laser fluence rates is the 
photomechanical mode of laser therapy that is primarily used in ophthalmology for non-
invasive iridectomies and capsulectomies to puncture holes in the iris and remove tissue 
in the eye.
2
 Then, a step down in laser fluence yields the ablative mode that is also used 
in ophthalmology for treating keratotomy, various forms of keratophakia, and corneal 
ablation,
3-5
 and it is also used in angioplasty
6, 7
 and joint surgery.
8
 Another mode with yet 
lower fluence, is the photothermal mode, which has become prominent in the field of 
oncology for selectively treating cancer using photosensitive particles (e.g. endogenous 
chromophores, fluorescent dyes, and gold nanoparticles),
9-12
 and recently in laser 
immunotherapy for treating metastatic cancer.
13, 14
 In addition, at this level of irradiation 
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blood coagulation (thrombogenicity) can be achieved in small vessels.
15
 Then, at lower 
fluence rates below hyperthermia is the photochemical mode. Photodynamic therapy is 
most popular form of this mode for treating certain diseases by causing the generation of 
singlet oxygen species through photochemical reactions with non-thermal, low doses of 
light irradiation.
16, 17
 Finally, at low fluence rates light can be used for a number of 
biostimulation and wound healing treatments.
18
 Low laser level therapy (LLLT) that is 
part of this category has also been proposed to support treating tinnitus, epilepsy, pain, 
thrombosis, light hypersensitivity, physical trauma or surgery recovery, hyperlipidemia, 
and strengthening of the immune system.
19
 The application of light has found its way into 
a variety of different medical applications with varying intensities, wavelengths, and 
transmissions.  
Imaging as a medical diagnostic tool has been developed and used abundantly 
with new techniques and methods being developed aggressively in recent decades. Non-
optical imaging methods such as MRI, CT, US, X-ray, etc. are widely used to assist in the 
diagnosis, treatment, and monitoring of various diseases or injury. In light of the 
widespread advantages imaging provides physicians, every technique has inherent 
drawbacks and limitations whether it is resolution, acquisition time, sensitivity, 
specificity, safety, or cost. New imaging technology is constantly being investigated and 
tested to overcome or alleviate these limitations. Optical imaging has come to be widely 
used in biomedical imaging on account that its strengths can satisfy several of these 
criteria above competing technology. The use of optics can be less expensive, provide 
high-resolution and quick imaging time, be highly accurate, ensure minimal health risk, 
and designed to be portable or miniaturized. However, optical imaging techniques are far 
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from a universal answer to all imaging issues as they carry their own inherent limitations 
such as small field-of-view, shallow imaging depths compared to other modalities, and 
inability to detect certain biological parameters that other imaging techniques can detect. 
In essence, optical imaging fits into the biomedical imaging scene to offer certain 
advantages over other modalities but is also limited in capability compared to other 
modalities. In the next section, techniques and applications of optical imaging will be 
introduced and covered. 
1.2.Optical Imaging 
In the field of biomedical optics, optical imaging techniques are directed at the 
use of light for the visualization and investigation of biological tissues. Two modes of 
imaging are employed to collect a signal from tissue: transmission mode and reflectance 
mode. Using transmission mode, such as in conventional brightfield microscopy, light is 
propagated through a sample and collected by a detector on the opposing side as the 
source (see Figure 1A). In contrast, optical imaging that relies on reflectance mode 
operates by collecting light that has entered the sample, collided with molecules in the 
tissue, scattered in different directions, and ultimately exits the tissue and returns to a 




Figure 1. Transmission versus reflectance imaging modes. 
When light enters tissue it interactions with the molecules of the tissue as it 
propagates through. However, when light interacts with tissue subtle changes occur in the 
property of the light. Depending on the index of refraction, the light might be bent at 
different angels as it enter different substances in the tissue, and when it encounters 
cellular structures light protein fibers, cell membranes, organelles, nuclei, etc. the light is 
scattered in random directions. The degree of scattering is a function of the size, 
orientation, and refractive index of the structures the light collides with. An example of 




Figure 2. Light scattering in tissue. As light passes through each structural 
barrier, light is scattered causing the intensity of the propagating beam to 
be diminished. 
Another way that light interacts with tissue besides scattering is through 
absorption within tissue. Certain components of cells inherently absorb light. Main light 
absorbers in tissue consist of water, hemoglobin (both in its oxygenated form and 
deoxygenated form), and melanosomes (see Figure 3). Absorption peaks of these various 
constituents can be used as a diagnostic marker for their presence and concentration in 
tissue. Absorbed light can also be re-emitted through several mechanisms, such as 
fluorescence, Raman scattering, and others that are associated with specific energy shifts 




Figure 3. Absorption spectra for biological tissue. The various curves 
depict the absorption of predominant endogenous constituents of tissue, 
i.e., water, deoxyhemoglobin (Hb), oxygenated hemoglobin (HbO2), and 
melanin. Used by permission. Source: 
http://www.photobiology.info/Hamblin.html 
Light transmission in biological tissue is relatively high in the wavelength range 
of approximately 650 to 1400 nm. The lower limit of this range is impeded by scattering 
and absorption of native chromophores hemoglobin and melanin and the upper limit is 
caused by the increased absorption of water at longer wavelengths. With these 
endogenous molecules as the main obstacles of light, optical imaging is optimal within 
the range of 650-1400 nm, which is known as the “optical window” of tissue. In this 
range, optical imaging can be performed at deeper penetration in the infrared region (e.g. 
1300 nm) or with higher resolution in the visible-near-infrared region (e.g. 650-800 nm). 
Thus, optical imaging techniques must balance a close trade-off between resolution and 
imaging depth.  
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An assortment of popular imaging modalities (optical imaging as well as others 
such as MRI, CT, US, etc.) are presented in Figure 4 along axes that compare the 
achievable depth of penetration of each technique compared to their spatial resolution 
capability. Optical techniques cover a broad imaging range from microscopic (multi-
photon microscopy) to macroscopic scales (diffuse optical tomography). As can be seen 
in Figure 4, there exist a rough monotonic relationship between depth of penetration and 
spatial resolution that is also wavelength dependent.  
 
Figure 4. Spatial resolution versus depth of penetration for various 
imaging techniques. Abbreviations: CM: confocal microscopy; MPM: 
multi-photon microscopy; OCT: optical coherence tomography; LOT: 
laminar optical tomography; US: ultrasound; PAT: photoacoustic 
tomography; DOT: diffuse optical tomography; MRI: magnetic resonance 
imaging; CT: computed tomography; PET: positron emission tomography; 
SPECT: single-photon emission computed tomography. 
High-resolution optical imaging techniques, like confocal microscopy and multi-
photon microscopy on the lower left hand side of Figure 4, can achieve very high spatial 
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resolution but comparatively shallow depth penetration. With these high-resolution 
techniques, contrast is provided by staining, exogenous fluorescent probes, or 
endogenous fluorophores. Typically, these techniques are employed for 2D planar 
imaging. 3D imaging is possible using dynamic optics to adjust the focusing depth during 
image acquisition, but can only be acquired in scattering media (biological tissue) by 
beam scanning.  
 Conversely, deep penetrating optical imaging techniques, like diffuse 
optical tomography, offers the ability to image with a wide field-of-view but at the 
expense of lower resolutions (trade-off is on the order of 3 magnitudes for both 
parameters). Significant research in recent years has been dedicated to developing this 
technique for mammography screening as a viable option to replace current X-ray 
mammography.
20-22
 Currently, X-ray mammography utilizes ionizing radiation but this 
may be replaced soon with non-ionizing optical mammography techniques. 
 Between the two extremes of these optical imaging techniques (MPM and 
DOT) is optical coherence tomography (OCT), which is a reflectance based optical 
imaging technique that can provide microscopic to mesoscopic scale imaging with no 
need of exogenous contrast agents. The research presented in this thesis targets the 
translation of this imaging technique as it applies to possible uses in the field of 
nephrology. Specifically, we investigate if OCT can be used for applications in renal 
transplant and renal cancer patients. 
1.3.Optical Coherence Tomography 
Optical coherence tomography (OCT) is a non-invasive, high-resolution, 
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coherence-based imaging technology that uses infrared or near-infrared light to acquire 
cross-sectional images or three-dimensional (3D) volumes of the subsurface 
microstructure of superficial tissues. Since its emergence in the early 1990s,
23
 OCT has 
become a highly investigated imaging technology on account of its potential for medical 
diagnosis and monitoring of therapy non-invasively in vivo with resolutions approaching 
that of conventional histology.
24
 In situ and in vivo visualization of biological tissue at 
high resolution was not achievable with histopathology. OCT is a non-contact, 
interferometric imaging modality that can resolve subsurface structures non-destructively 
within intact tissue. With this capability OCT can offer an “optical biopsy” approach for 
tissue that cannot be excised such as retinal tissue and vascular tissue, and easy access to 
the inner surfaces of hollow organs and body cavities such as the gastrointestinal tract 
and urinary tract/bladder.  
Cross-sectional OCT images are produced by scanning the beam across the 
surface of the sample and collecting a series of axial (vertical) profiles which formulate a 
two-dimensional (2D) image. Axial profiles of the sample are produced by low-
coherence interferometry of the backscattered light from the sample. The magnitude of 
this backscattered light at a given depth in the axial profile is represented in a 2D cross-
sectional image by the pixel intensity at the corresponding point for a particular echo time 
delay. A more thorough technical explanation regarding OCT will be provided in the 
following section(s). 
1.3.1. Light Source, Interferometry, and System Design 
OCT forms an image representing the internal structure of a sample by measuring 
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echo delays and the intensities of back-reflected light. Since the velocity of light is too 
fast to clock with electronic equipment, the timing of echo delays cannot be directly 
measured. The way OCT determines the location of optical echo delays is through a 
technique called low-coherence interferometry. In low-coherence interferometry, back-
reflected or backscattered light is measured against light that travels a known reference 
path. The classic Michelson interferometer design is shown below in Figure 5. 
 
Figure 5. Michelson interferometer diagram used for performing low-
coherence interferometry. 
Because detector response times cannot compare with the high speed of light, the 
Michelson interferometer compares light backscattered from a sample with light from a 
“reference” mirror, which consists of a mirror with a predetermined path length 
correlating to a specific depth location in the sample. Michelson interferometry operates 
by splitting a beam from a low-coherence light source into two separate paths using fiber 
optics to control the path of the light. One “arm” of the interferometer contains a 
modulating probe that focuses the beam and can scan it across the surface of the sample. 
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This “arm” is responsible for directing the beam and then additionally collecting 
backscattered light as it returns from the sample. The other “arm” contains the known 
reference path which is a mirror that causes the light to travel a specified distance. The 
total round-trip path length (Lr) for the “reference” arm is equal to 2nlr where n is the 
index of refraction (typically equal to 1.0 for air) and lr is the distance the mirror is away 
from the beam splitter where the light is initially separated. The path length of the 
“sample” arm is similar Ls = 2nls. Interference between the sample and reference signals 
returning from the sample and the mirror only occurs within the “coherence gate 
(length)” of the light source. For a low-coherence light source the gating window is equal 
to Δz as show below in Figure 6. 
 
Figure 6. Coherence fringe for low-coherence light source. λ0 is the center 
wavelength, Δz is the full-width, half-maximum (FWHM) distance, and 
ΔL is path length difference between the sample and reference arm. λ0/2 is 
the fringe period. 
This means that light interferes or forms an interference pattern if the path length 
between the two arms of the interferometer is within the coherence length of the light. 
When the path length is within the coherence “gate” an interference fringe is formed 
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according to the recombination of light returning from each arm. However, only a 
fraction of the ballistic photons entering the sample are scattered and re-collected by the 
objective lens. These backscattered photons can enable the measurement of the sample‟s 
optical properties, specifically of interest is the light attenuation coefficient (μt). A 
conventional schematic diagram of OCT is shown below in Figure 7. The reference and 
sample arm from the Michelson interferometer design illustrated above in Figure 5 are 
labeled accordingly in Figure 7 below. 
 
Figure 7. Fourier-domain, swept-source optical coherence tomography 
(OCT) system setup. Axial and transverse resolution, imaging speed, 
imaging depth, and field-of-view parameters are listed in Table 1 below. 
OCT system schematic abbreviations, FC: fiber coupler, PC: polarization 
controller, C: collimator, MZI: Mach-Zehnder interferometer (frequency 
clock), M: mirror, BD: balanced detector, DAQ: data acquisition board, 
DCG: dispersion compensating glasses, OBJ: objective. Light path lengths 
not proportional to actual distance. 
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As depicted above in Figure 4, OCT can have a range of penetration depths and 
spatial resolutions. The specifications listed below in Table 1 are general specifications 
for the OCT system but can be altered through using different optics or light sources. 
Table 1. OCT System Specifications. 
OCT Specifications 





1D: 16 kHz 
2D: 30 Hz 
3D: 17s 
(variable) 





By scanning a beam across the surface of a sample, a 2D cross-sectional image of 
the sample can be generated showing the backscattered light intensity with respect to 
penetration depth (see Figure 8). This is performed by stacking adjacent axial scans 
together as the beam moves laterally across the surface of tissue. By repetitively scanning 
2D cross-sectional images in this manner and stepping the beam across the surface of a 
sample in the direction perpendicular to the 2D scanning, a 3D volumetric image data set 
can be obtained enabling the generation of en face (lateral plane) images that are similar 
to normal light microscopy, and furthermore, enabling even oblique slices with arbitrary 
 15 
 
orientation to be extracted.  
 
Figure 8. Formation of OCT image. OCT measures the backscattering 
intensity as a function of depth. Cross-sectional images are generated by 
scanning a beam across the tissue.  A gray scale or false color image can 
then be displayed representing the reflected light intensity at every depth 
point and lateral position. 
The coherence length of the light source and the spot size of the beam focus on 
the sample are the determining factors that determine the axial and lateral resolutions of 
the system. Axial and lateral resolutions are dependent upon the light source and optical 
components employed in constructing the OCT system. These two parameters of our 
OCT system design will be discussed individually in more detail in the following 
sections.  
As was shown in Figure 3, biological tissue has less absorption and scattering in 
the near-infrared (NIR) / infrared (IR) wavelength range (700-1300 nm).
25
 This region is 
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known as the “water window” or “optical window” because frequencies of light in this 
NIR/IR region are able to transmit better than regions lower or higher than this window. 
Therefore, to maximize penetration depth the wavelength of the light source should be 
such that absorption of the photons in the sample is minimized. The OCT system used in 
this research employs a 1300 nm swept-source laser with ~100 nm bandwidth. The 
normalized power spectrum of our light source is show below in Figure 9. 
 
Figure 9. OCT swept-source laser power spectrum. The center 
wavelength (λ0) is ~1330 nm and the FWHM bandwidth (Δλ) is ~112 nm. 
These exact specifications are listed in this thesis in general terms as λ0 = 
1300 nm and Δλ = 100 nm since the spectrum has slightly changed over 
time during the course of the experiments. 
Since imaging depth is wavelength dependent, the longer wavelength we use 
(1300 nm) offers better penetration than alternative light sources around 800 nm by a 
factor of approximately 2.
26
 At NIR wavelengths light scattering is the predominant 
factor in signal attenuation as the degree of absorption is drastically less. But, OCT 
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contrast is a function of both scattering and absorption as incident light propagates 
through tissue and is backscattered from collision with internal structures and travels 
back to the objective lens. Due to the scattering and absorption effects of tissue, OCT has 
a relatively shallow depth of penetration. On account of the interactions between the light 
and tissue, the maximum imaging depth for OCT is only ~2-3 mm.  
Light is attenuated both as it enters into tissue and as it travels back out. 
According to the Beer-Lambert law, light attenuation in tissue follows an exponential 
decay function. The total attenuation coefficient (μt) of the ballistic photons is the sum of 
absorbed (μa) and scattered (μs) light (μt = μs + μa). But, because light scattering is much 
greater than absorption in the NIR region (μs >> μa), the total attenuation coefficient can 
be approximated by the exponential attenuation due to scattering alone (μt ≈ μs). The 
scattering coefficient (μs) is a parameter that describes the probability per unit length of a 
photon being scattered in the tissue. Tissue/cell distribution, size, density, and orientation 
are all critical factors affecting light scattering. Tissue scattering properties are highly 
dependent on changes in the refractive index at object boundaries (e.g. cell membranes, 
protein fibers, etc.). Raising the refractive index mismatch between components within 
tissue increases the relative scattering of light as it enters the tissue. 
1.3.2. Axial Resolution 
OCT axial resolution is dependent upon the width and shape of the bandwidth 
from the light source and typically ranges from ~1-15 μm. In order to achieve a high axial 
resolution, the coherence length of the light source has to be as short as possible because 
axial resolution is determined by the coherence length of the light source. The coherence 
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length (Δz) is related to the center wavelength (λ0) and the full-width-half-maximum 
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 Given that the coherence length of the light source in medium with refractive 
index n is Δz/n, some light sources with large bandwidth can offer super-high axial 
resolution of approximately 1 μm in tissue.
27
 
Using a 1310 nm center wavelength light source with a 100 nm bandwidth, the 
theoretical axial resolution is 7.45 μm. Experimentally, the calibrated axial resolution 
using a stationary mirror as a point reflector is ~16 μm in air and ~12 μm in tissue as 
demonstrated in Figure 10. This is the axial (vertical) resolution of the OCT light source 





Figure 10. OCT axial resolution calibration using stationary mirror. 
Vertical width of mirror represents coherence length of the light source. 
(A) Cross-section image of stationary mirror in air. (B) Line plot of 
dashed line in (A) across mirror. Vertical resolution is defined as the 
distance at 50% FWHM. In air (n=1.0), the axial resolution is ~16 μm, and 
thus, in tissue (n=1.33) it is ~12 μm. [n=refractive index] 
Also, our OCT system‟s imaging depth was determined experimentally to be 2.63 
mm in air and therefore is 1.98 mm in tissue (see Figure 11). To determine the imaging 
distance in air, a stationary mirror is moved vertically exactly a certain specific distance 
using a precise micromanipulator with a microscope stage. Then, the full distance of the 
OCT image depth can be extrapolated from that movement. The change in the index of 
refraction from air (n=1.0) to tissue (n=1.33) decreases the imaging depth by the inverse 
factor of the index of refraction. Thus, an imaging depth in tissue is equal to 2.63 mm 




Figure 11. Depth of penetration calibration. Stationary mirror (indicated 
by horizontal line passing through square data cursor) was moved 
manually exactly 1mm vertically. The difference in pixels represents a 
depth of 1 mm in air. With 512 pixels per axial scan, the OCT imaging 
depth in air (n=1.0) was determined to be 2.6256 mm and therefore is 
1.9797 mm in tissue (n≈1.33). [n=refractive index] 
1.3.3. Transverse Resolution 
OCT transverse resolution is dependent on the interrelation between the scan size, 
sampling density, and laser spot size formed according to the numerical aperture (NA) of 
the objective lens (focusing component) in the sample arm. The scan size is the physical 
distance which the beam travels across the surface of the sample and the sampling density 
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is a function of the step size of the beam (i.e. the number of axial scans that are recorded 
per 2D image). However, the minimum transverse resolution is ultimately determined by 
the magnification of the objective lens. Low NA lenses achieve a large spot size but 
longer depth of focus. In contrast, high NA lenses achieve a smaller spot size but shorter 
depth of focus. The relationship between the transverse resolution and depth of focus is 
depicted in Figure 12. The focusing gate is the light profile that is focused into the lens. A 
thinner focusing “waist” from a high NA lens can achieve higher transverse resolutions 
than a wider “waist” from a lower NA lens. The “waist” of the focusing gate is the 






Figure 12. Focusing gate and the effect on transverse resolution. Low NA 
focusing achieves lower transverse resolution but longer depth of focus. 
High NA focusing offers the inverse, high transverse resolution but shorter 
depth of focus. The axial resolution is represented by Δz and the 
transverse resolution by Δx. For OCT, the axial resolution is dependent on 
the coherence length of the light source alone and is not affected by the 
NA of the focusing lens.  
The theoretical transverse resolution (Δx) of an objective lens can be 










where λ0 is the center wavelength of the light source bandwidth, f is the focal distance 
(working distance), and d is the diameter of the objective lens. However, a more precise 









x  (3) 
where λ0 is the wavelength of the light source, n is the refractive index, and θ is half the 
maximum angle for the possible light that can enter/exit the objective lens.
28
 Wider 
diameter lenses and shorter focal distances increase the transverse resolution but at the 
expense of depth of focus in the axial (vertical) dimension. For example, with a 10x 
(NA=0.25) objective lens and 1310 nm wavelength light source, the upper limit of the 
transverse resolution is equal to 2.28 μm. This calculation, however, does not account for 
the beam profile (size) or dispersion effects inherent in the optics. Experimentally, using 
the 1951 USAF resolution chart the upper limit of the transverse resolution for our OCT 
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microscope with 10x objective was determined to be ~2-3 μm (see Figure 13A). But, the 
resolutions of the X and Y (horizontal and vertical) dimension are not exactly equivalent 
because the scan sizes are slightly different between the two dimensions. The transverse 
resolution can be estimated by determining the separation distance between elements at a 
contrast intensity (C) of ~26% (see Figure 13C).
28









  (4) 
where Ip is the peak intensity value of the elements in the group and IV is the valley 
intensity between the group elements. Using this method, the transverse resolution is 
determined to be ~2.7 μm. Another way to determine the transverse resolution is using 
the edge spread function (ESF) by finding the distance it takes to change from 10% 
(background intensity) to 90% (object intensity) at the edge of a flat object (i.e. vertical 
knife-edge).
29
 According to this method, the transverse resolution was determined to be 
~3.15μm, which is a little higher than the value obtained with the first method. This 
might be due to some error inherent in the edge spread function. If the scan size is 
increased but the sampling density is kept the same, the transverse resolution will 
decrease proportionally with the increase in scanning distance. Because different system 
designs and optics change the transverse resolution, the transverse resolution of the 





Figure 13. Transverse resolution determined by 1951 USAF resolution 
chart. (A) 1×1 mm en face image of resolution chart. The lowest 
resolvable element according to contrast is Group 7, Element 4 (G7E4). 
Group 7 is labeled and Element 1(G7E1) is located above the label on the 
right side of the image with descending sizes to Element 6 next to the L1 
label on the left side of the image. (B) Line plot of L1 line in (A) across all 
Group 7 (G7) elements. (C) Contrast transfer function (CTF) of Group 7 
elements in (A). (D) Line plot of L2 depicting edge spread function (ESF). 
Distance between normalized intensity at 90% and 10% is identified 
(arrow).  
1.3.4. Sensitivity 
Sensitivity is defined as the signal range above the noise level that is detectable. 
This can be discerned by determining the minimum reflection from a planar surface (e.g. 
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mirror) that gives rise to a signal matching the noise level. The sensitivity can be referred 
to as the signal-to-noise ratio (SNR) and can reach values exceeding 100 dB, which is 
measured on a logarithmic scale. Therefore, it is possible to detect reflected photons from 
the sample that consist of 1·10
-10
 of the incident light. The OCT system used in the 
studies has sensitivity between 92-95 dB. 
1.3.5. Phase Stability 
Light that interacts with moving reflectors (e.g. red blood cells) undergoes a shift 
in phase according to the Doppler Effect, much like the siren of a passing ambulance. 
Detecting phase shifted light depends on the phase stability of the light source and optics. 
Calibrating the lower limit phase shift can reveal the smallest increment of discernible 
difference in signal for moving particles. Using a stationary mirror, the fluctuations in 
phase of back-reflected light can provide a means to approximate the phase stability of 
the OCT system (see Figure 14). However, fluctuations in phase should be recorded with 
a scanning beam because the jitter and induced-phase shift from the galvanometer mirrors 





Figure 14.  OCT phase stability. (A) OCT intensity and (B) corresponding 
phase images. Arrows in (B) indicate phase fluctuations that are not 
displayed in the OCT intensity image (A). (C) Plot of the phase taken from 
within the region indicated by the white box in (B). Red dashed lines 
indicate standard error of phase noise.  Scale bar = 1 mm. 
According to our experimental calibration, the minimum detectable phase shift is 
~0.1 rad which corresponds to ~100 μm/s axial velocity (shown in Figure 14C). 
Improved velocity sensitivity can be attained by using an axial scan gate window 
(convolution). Using a 5 axial scan window, the minimum detectable phase decreases to 
~0.07 rad which corresponds to ~60 μm/s. The gate window and ensemble length 
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(number of depth points to include in 2D convolution), is inversely proportional to the 
detectable phase shift. Thus, the larger the gate window and ensemble length is the 
smaller the phase shift that can be detected. 
1.3.6. Advantages of OCT 
Technical advantages of OCT as an imaging technology: 
1) Reduced radiation exposure compared to alternative imaging with similar 
scale resolution (e.g. μCT) 
2) Relatively low cost, durable, robust, and transportable 
3) Higher resolution than US and deeper penetration and faster 3D imaging 
speeds than confocal microscopy  
In clinical medicine, the attractiveness of OCT is encapsulated in the “optical 
biopsy” which it can provide in situ. To be able to visualize biological tissue in situ 
without contact and without tissue excision is something not achievable with other 
imaging modalities and especially not with conventional core biopsy.  
Clinical advantages of OCT as an imaging technology: 
1) Image tissue in situ where core biopsy is not an option 
2) Image tissue in hollow organs using miniaturized, fiber-optic probes 
3) Image locations deep within solid organs that are not easily accessible 
4) Image in real-time 
The backscattered light collected by OCT offers more than only qualitative 
visualization of tissue structure based on the amplitude of the light; the phase and 
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polarization of light provides a means to perform quantitative analysis of the light for 
simultaneous functional imaging. For example, shifts in the polarization state can 
determine properties of the tissue such as birefringence,
30, 31




1.3.7. Clinical Potential of OCT 
Minimally-invasive techniques, such as laparoscopic surgery, have been evolving 
into a standard of care for urologic surgery by having the benefits of decreased morbidity, 
shortened hospitalization time, and quicker recovery to full activity compared to open 
surgery.
34-37
 With the positive impact of minimally-invasive procedures, minimally-
invasive optical imaging, especially OCT, is expected to play more important roles in 
clinical kidney imaging. OCT can be readily interfaced with fiber-optic catheters, 
endoscopes, laparoscopes, and needle imaging probes to image inside the body.
38-41
 
Minimally-invasive OCT imaging has been demonstrated in the human cardiovascular 
system,
42






 and others, and 





 and others. Medical imaging technologies, such as US and MRI, 
have been developed to aid in the diagnosis of acute kidney injury;
55
 however, the 
resolutions of these standard medical imaging systems are limited for they are not able to 
resolve the fine structures within the kidney nephron (e.g., glomeruli, tubules, vessels). 
The depth of OCT is shallow compared to other clinical imaging modalities, but the 
image resolution of OCT is 10 to 100 times greater than conventional US, MRI, or CT. In 
addition, the imaging depth of OCT is comparable to that typically sampled by core 
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biopsy and is therefore potentially able to non-invasively evaluate kidney status. 
Furthermore, OCT is low cost, portable, and ideally suited for surgical suites. Compared 
to core biopsy, OCT is non-invasive with minimal risk of infection and trauma to the 
kidney (such as hemorrhage). Also, multiple regions can be surveyed in real time to 
obtain an overall measure of the kidney‟s status. Therefore, minimally-invasive OCT 
holds great potential for diagnosis and management of renal diseases and is the defining 
motivation for the continuation of research as a biomedical imaging modality. 
1.4.Doppler Optical Coherence Tomography 
Another advantage of OCT, that is paralleled in ultrasonography, is the ability to 
detect motion in tissue by analyzing the Doppler phenomenon to calculate velocity.
49, 56, 
57
 Doppler OCT (DOCT) is a functional extension of OCT that can sense moving 
scatterers thereby enabling real-time imaging of blood flow in tissue by combining the 
high spatial resolution of OCT with the high sensitivity of the Doppler effect.
50, 58-62
 
Velocity information obtained from DOCT has been used to measure microvascular 









 among others. Moving reflectors within the tissue induce a 
Doppler frequency shift in the backscattered light, which when combined with the 
reference beam, is detected as a complex signal, denoting signal magnitude and phase. A 
change in the complex signal from the interference pattern indicates a phase shift from 
the sample signal. Positive phase shifts and negative phase shifts can be color-coded in 
order to identify the direction of motion with respect to the scanning beam. Color-coded 
DOCT images can then be overlaid on the OCT structural images to provide a powerful 
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visualization imaging modality of moving scatterers in real time, such as red blood cells 
in vivo. 
1.4.1. Principle and Calculation of Doppler Velocity 
OCT fringe data contains both magnitude and phase information from the 
interference pattern created by the combination of the backscattered light from the sample 
arm with the reference arm. Using the phase information contained in the complex 
portion of the OCT signal, the Doppler frequency shift at each depth position can be 
computed. Given that the OCT complex signal (S) can be expressed as: 
jQIS   (5) 
where I is the real component and Q is the imaginary component. Acquired 2D OCT 
images can then be stored as complex arrays Im,n and Qm,n with m and n denoting the 
indices in the depth and lateral dimensions, respectively. OCT intensity images concern 
only the magnitude of the backscattered light at each particular pixel. The magnitude of 
















2 1  (6) 
Where M and N define a specified averaging window. M is the depth of the 
window (also known as the gate length), and N is the number of axial scans to include 
(also called the ensemble length). The averaging window performs a type of convolution 
of the image improving the signal-to-noise ratio but also lowering the resolution. Since 
OCT intensity images contain a large dynamic range, the logarithm of the intensity of the 
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backscattered light is used to display OCT structural images. 
The Doppler frequency shift associated with the structural OCT image can be 
computed from the corresponding complex component of the signal at each pixel 
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where v is the mean velocity, λ0 is the center wavelength of the light source, fD is the 
Doppler frequency shift, nt is the tissue index of refraction (~1.33), θ is the direction 
angle of the moving scatterer, fa is the axial scanning frequency of the beam. Computing 
the mean shift between adjacent axial scans using the arctangent function means that the 
Doppler frequency shift (fD) is defined in all four quadrants but has output values only 
ranging from –π to +π. The value of M and N for DOCT are typically not the same as for 
OCT. Increasing the averaging window size can help improve the signal-to-noise ratio 
but at the consequence of lower resolution. But, if high noise levels are present in the 




Figure 15. DOCT calibration using tube phantoms with intralipid (IL). IL 
was pumped through capillary tube at defined velocity intervals using 
syringe pump. Scale bar = 1 mm. 
1.4.2. Detection Limits of DOCT 
The detectable Doppler velocity range is defined according to the minimum and 
maximum non-aliased velocities that are dependent upon the scanning beam frequency 
and the phase stability of the interferometer and optoelectronics. The maximum DOCT 
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with λ0 = 1310 nm, fa equal to 8.0 kHz, and nt equal to 1.33 for tissue, the maximum non-
aliased velocity achievable with our system is 3.91 mm/s. Velocities exceeding this value 
will be aliased from discontinuities in accordance with the limits of the arctangent 
function. In principle, higher velocities can be achieved by “unwrapping” the aliased 
discontinuities in the phase, but it become increasingly challenging in the presence of 
 33 
 
noise. However, there is an upper limit to phase unwrapping techniques since the velocity 
estimation accuracy of the phase-resolved method diminishes with increasing flow 
velocity. 
The minimum detectable velocity is dependent on the phase stability of the 












V  (10) 
with λ0 = 1310 nm, fa equal to 8.0 kHz, nt equal to 1.33 for tissue, and Δφ equal to 0.9 rad 
(see Figure 14C, standard error value), the minimum detectable velocity with our system 
is ±53 μm/s. This agrees with published values of the phase noise for our OCT system.
73
 
The minimum detectable velocity is relatively fixed according to the performance of the 
system‟s hardware (optic and electronic components). Improving the stability of the laser 
source could be a way to lower the minimum detectable velocity of the system. 
1.4.3. Determination of Flow with DOCT 
In order to quantify blood flow, several algorithms have been published but most 
are dependent upon the angle between the directional flow vector and the scanning 
beam.
54, 74
 Recently, however, an algorithm quantifying flow rate independent of the 
velocity vector orientation was published which demonstrated the ability to integrate the 
velocity profile of a bisected vessel in order to obtain its total flow rate.
75
 Flow can be 
calculated by integrating over the en face (lateral plane) image to eliminate the angle 




Figure 16. Calculation of flow from DOCT velocity. Integrating over the 
en face lateral cross-section cancels the cosine angle dependence of the 




Therefore, to validate our DOCT imaging system we quantified the flow rate in 
several tube phantoms. By performing 3D DOCT imaging on the tube phantoms with a 
constant (known) flow rate, the measured flow rate from the DOCT images was 
compared with the specified flow rate value. Figure 17A displays the results of these 
comparisons. The set flow rate in the tube phantom was 0.1702 μl/s and the value 
obtained from integrating over the lumen of the tube phantom in three separate trials was 
0.1728 ± 0.0031 μl/s. Figure 17B,C,D display en face images of the capillary tube at 
varying angles (with respect to the vertical axis). Different vertical angles will change the 
vertical component of the fluid velocity in the tube thereby yielding different DOCT 
phase shifts. The vertical velocity represented by the intensity of the red/yellow color 
shows decreasing intensity (Figure 17B compared to Figure 17C,D) when increasing the 
angle away from the vertical axis (i.e. making the tube direction more horizontal). But by 
integrating over the en face lateral cross-section of the tube, the flow calculation is not 
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dependent on the tube orientation direction. 
 
Figure 17. DOCT flow rate calibration using capillary tubes and 
scattering media. (A) Flow rate computed from DOCT en face velocity 
map images. Actual flow rate indicated by horizontal dashed line. (B-D) 
DOCT en face velocity map images with specified tube angle and depth. 
The flow rate presented in (A) was obtained from (B-D) by integrating the 
velocity within lumen of tube phantom (enclosed by yellow dashed line). 
DOCT colormap indicates positive vertical velocity (red/yellow) and 
negative vertical velocity (blue/cyan). Scale bar = 500 μm. 
Examples of the en face lateral cross-section velocity profile can be seen in Figure 
17B-D which shows the vertical velocity map across the plane of the tube at a specific 
depth. Our calibration results agree closely with the set flow rate in the tubes 




2. Background on the Clinical Application 
2.1.The Renal System 
Metabolic waste is a natural by-product of cellular function and must be 
efficiently excreted in order to not retain toxic compounds in the body. Waste products of 
primary importance are urea and uric acid, which are waste molecules from protein 
metabolism and nucleic acid breakdown. But, just as significant as the need to rid the 
body of urea and uric acid is the need to maintain electrolytic homeostasis by regulating 
the body‟s water and inorganic salt content. A deficiency in the body‟s general ability to 
excrete waste products results in life-threatening conditions, such as metabolic acidosis, 
hyperkalemia (elevated blood potassium levels), and uremia (elevated blood urea levels). 
In addition to filtering and excreting metabolic waste products and balancing the body‟s 
internal environment, the renal system also functions to control blood pressure, 
intravascular volume, and stimulate the production of red blood cells in the bone marrow 
by secreting the hormone erythropoietin.
76, 77
   
Waste products produced within the body are transported to the renal system via 
the blood through the circulatory system. The kidney is the organ in the renal system that 
performs the filtration of the blood and collection of urine, which it then simply passes to 




Figure 18. Frontal section of the human kidney. Major structures such as 
the medulla, cortex, and major calyx can be seen as well as the overall 
anatomy of the organ. Used by permission.
78
  
Figure 18 shows the gross anatomy of the kidney with the major anatomical 
features labeled. However, the disposal of waste products in the blood takes place on the 
microscopic level in subunits of the kidney called nephrons (see Figure 19).  
1. Renal pyramid 
2. Interlobar artery 
3. Renal artery 
4. Renal vein 
5. Renal hylum 
6. Renal pelvis 
7. Ureter 
8. Minor calyx 
9. Renal capsule 
10. Inferior extremity 
11. Superior extremity 
12. Interlobar vein 
13. Nephron 
14. Renal sinus 
15. Major calyx 
16. Renal papilla 





Figure 19. Kidney nephron. Major components are identified with the 




The component of the nephron that does the actual filtering of the blood, though, 
is the glomerulus (#6 in Figure 19), which contains a bed of fenestrated capillaries 
allowing the rapid transport of water and other small solutes out of the blood and into the 






Figure 20. Kidney glomerulus (filtering component in the nephron). 
Glomeruli consist of a ball (“tuft”) of intertwined capillaries that seep 
plasma, ions, small proteins, and waste molecules out of the blood into the 




Of paramount importance in the ability of the kidney to perform proper filtration 
is the amount of blood flowing to the glomerulus and the rate at which waste products are 
filtered out of the blood by the glomerulus. Any substantial decline in either of these 
parameters would directly impair the ability of the kidney to effectively filter the blood. 
Several disease states can result in altered renal blood flow (RBF) and changes in 
shape and size of kidney microstructures. For example, during renal surgery, injury to the 
kidney can result from ischemia (deprivation of blood/oxygen), which then, in turn, can 
result in some degree of renal dysfunction, or during kidney transplantation, if the 
transplanted kidney experiences reperfusion injury, this can result in altered blood and 
subsequently delayed graft function of the donor kidney. Also, in the transition from 
normal parenchyma (kidney tissue) to cancerous tissue, renal tissue undergoes 
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architectural changes that affect the shape, size, density, and general constituents of the 
tissue. For example, renal cancer disrupts the homogenous renal parenchyma that is 
observed in health, normal renal tissue (see Figure 21). Uriniferous tubules are regularly 
dispersed (small circular, dark spots beneath bright surface layer) but in the tumor region, 
aberrant tissue architecture (heterogeneous tissue patterns) is seen and highly 







Figure 21. Normal versus cancerous ex vivo kidney tissue. (A) Normal 
tissue exhibits clear capsule and relatively uniform parenchyma with 
densely packed uriniferous tubules (small dark circles). (B) Renal cancer 
tissue exhibits generally disorganized tissue architecture with aberrant 
tubular structures unevenly distributed throughout with no discernible 
capsule on the kidney surface. Scale bar = 500 μm. 
Therefore, in order to identify injury caused by renal ischemia and minimize the 
risk of delayed graft function, or to distinguish cancerous tissue from normal renal tissue, 
imaging of kidney microstructure and blood flow can provide critical parameters that can 
gauge the status and function of the kidney and identify cancer regions, which is vital to 
know in order to provide optimal patient treatment during renal surgery. 
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3. Rat Kidney Blood Flow Imaging 
3.1.Introduction 
Intrarenal hemodynamic abnormalities are thought to be a primary factor 
associated with the onset and progression of acute injury,
81
 and other various 
nephropathies like diabetic nephropathy,
82, 83
 and focal segmental glomerulosclerosis.
84
 
Real-time assessment of renal morphological and hemodynamic changes could help to 
evaluate the kidney condition and offer valuable information to predict the prognosis of 
injury or disease lending to the development of patient-specific management strategies. 
Currently, though, there is no sensitive and objective tool for direct monitoring of renal 
microcirculatory changes in the clinic. The ability to monitor alterations in renal 
microcirculation due to vascular or glomerular disease may improve diagnostic and 
therapeutic interventions for renal health care.  
Renal blood flow (RBF) has been monitored using a number of different imaging 
modalities including positron emission tomography (PET),
85-90
 and magnetic resonance 
angiography,
91-94
 Doppler ultrasound (US),
95-98
 and contrast-enhanced (CE) US.
99, 100
 
While these techniques allow for non-invasive, wide field-of-view imaging, they do not 
have sufficient resolution to detect changes in renal microcirculation (glomerular). 
Regarding kidney transplantation, studies have suggested that blood perfusion within 
glomerular capillaries may be correlated with intermediate and long-term graft 
function.
101, 102
 Therefore, immediate detection of microcirculatory changes could provide 






Optical imaging techniques, though, that have higher resolutions and greater 
sensitivities could be a more feasible method for monitoring and evaluating 
microcirculatory changes, especially in an intra-operative setting. Several optical imaging 





 have demonstrated the ability to image kidney microstructure 
and function (blood flow and filtration rate) on animal models, but the penetration depth 
has been limited to several hundreds of microns,
111
 and they require the need to 
administer contrast agents to determine flow. Therefore, using these imaging modalities 
for human studies poses certain challenges due to the capsule surrounding the human 
kidney, which can be several hundred microns thick, and the need to inject contrast 
agents into the patient. 
Optical coherence tomography (OCT)
23
 and its functional extension Doppler OCT 
(DOCT)
68
 are emerging imaging technologies that have the capacity to provide real-time 
images (i.e., immediate imaging) of tissue in a non-invasive fashion (i.e., a non-
destructively) with high-resolution near that of conventional histopathological images. 
Previous studies by us have demonstrated the ability of OCT to resolve the renal 
corpuscle and uriniferous tubules
112
 and evaluate the real-time morphological changes in 
these structures associated with ischemia-reperfusion injury in vivo.
113
 Also, we have 
previously demonstrated that OCT can penetrate the kidney capsule surrounding human 
kidneys thereby enabling the characterization of renal tubules, glomeruli, and cortical 
blood vessels in fixed human kidneys.
114, 115
 OCT represents a laser echo microscopy and 
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High-speed, Fourier-domain DOCT can be used to visualize blood flow non-
invasively by measuring Doppler frequency shifts in the OCT interference signal caused 
by moving scatterers that are label-free, such as red blood cells.
117
 DOCT has been used 





 and gastrointestinal tract,
124
 among others. Thus, DOCT 
imaging of kidney blood flow has demonstrated translational potential.   
In the present study, our objective was to demonstrate the feasibility of using 
Doppler OCT (DOCT) to observe microcirculation within the living kidney in real time 
and quantitatively compare physiologically induced changes. 
3.2.Material and Methods 
3.2.1. Optical Coherence Tomography (OCT) and Doppler OCT 
A high-speed, high-resolution OCT system was used in this study. The details of 
the OCT system have been previously described.
114
 Briefly, a Fourier-domain OCT 
system consisting of a swept-source laser with 100 nm bandwidth at 1310 nm center 
wavelength yielding an axial resolution of ~12 μm in tissue was used. A 10x objective 
(Olympus Plan N, NA=0.25) was used in the sample arm to achieve a lateral resolution of 
~2-3 μm determined by USAF resolution target. The laser source operated at a sweep rate 
of 16 kHz allowing a series of 2D cross-sectional images to be captured in real time to 
form a 3D data set (Voxel size: 1024 [X] by 256 [Y] by 512 [Z]; Dimension: 0.280 mm 
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[X] by 0.325 mm [Y] by 1.90 mm [Z]; acquisition time <20 sec). OCT fringe data was 
acquired to obtain both amplitude and phase information after Fourier transform, and 




Figure 22. OCT/DOCT Microscope Setup. Abbreviations: XY: 
galvonometer; M: mirror; DM: dichroic mirror; L: lens. 
3.2.2. Animal Model and Experimental Setup 
The animal protocol has been approved by the committees on animal care and use 
in both the University of Maryland and Georgetown University. Male Munich-Wistar rats 
(n=3, ~400 g) were used in this study. This strain of rat has numerous superficial 
glomeruli in the outer cortex that are accessible for observation.
125
 Rats were regularly 
fed normal rat chow with free access to water at all times. During the study, rats were 
anesthetized by intraperitoneal injection of pentobarbital sodium (100 mg/kg body 
weight) and monitored routinely by tactile stimulation with supplemental anesthetic 
added as needed to maintain initial depth of anesthesia. After being secured on a portable 
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surgical apparatus, the left kidney was exposed through laparotomy of the left flank 
region and the kidney was securely placed in a lucite holder. The right femoral vein was 
then cannulated with polyethylene tubing for administration of pharmacologic agents. 
Rats were then placed beneath the DOCT microscope for in vivo imaging. To induce 
alterations in renal blood flow, 0.1-0.2 ml mannitol (250 mg/ml), which increases renal 
blood flow,
126-128
 and 200ng/kg body weight angiotensin II,
129
 which decreases renal 
blood flow,
130-133
 were administered by a bolus injection into the femoral vein. Three 
injections of mannitol at ~45 min intervals were performed followed by DOCT imaging 
after each injection and then a final injection of angiotensin II was given 10 min after the 
third mannitol injection and then followed by DOCT imaging. DOCT imaging was also 
performed approximately 15-20 min after each infusion of mannitol when the physiologic 
effects of the drug were diminishing. Data taken during this period is labeled “recover” to 
distinguish it from the data taken immediately after each mannitol injection. At each 
stage, multiple glomeruli (n ≥ 3) from different locations were imaged. Thus, the same 
glomeruli were not re-imaged at each stage due to the fact that multiple glomeruli were 
located and imaged at each stage by surveying different regions of the kidney cortex. 
3.2.3. OCT/DOCT Image Processing and Quantification 
Glomeruli were located by scanning the surface of the cortex, and 3D data sets, 
including the fringe data for Doppler analysis, were acquired for each glomerulus (total 
n=44). OCT intensity images as well as DOCT images were computed from the fringe 
data for each frame in the 3D data sets.
134
 DOCT images were computed using a 5×5 
binning window (gate length = 5, ensemble length = 5). To display the spatial correlation 
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between the OCT and DOCT images, OCT/DOCT fused images were constructed where 
the DOCT color images were overlaid on the grayscale OCT intensity images using a 
transparency mask based on a DOCT threshold that eliminated the background leaving 
only the higher DOCT signals opaque. Quantification of single glomerular 
microcirculation parameters was performed offline using a custom image analysis 
program written in Matlab (Mathworks Inc., Natick, MA, USA) by our lab. Algorithm for 
quantification parameter is given after explanation (see Figure 24).    
The glomerular volume (GV) was computed from the OCT intensity image 




GV A  (11) 
where SA is the surface area through the mid-section of the glomerulus and h is the height 
of the glomerulus. The surface area and height of each glomerulus was manually selected 
by encircling the perimeter of the glomerulus in cross-sectional and en face images 
passing through the center of glomerulus. The 2/3 scaling factor converts the cylindrical 
geometry, which is initially computed from the height and radius of the glomerular 
boundary that is manually selected for each data set, to the more realistic elliptical or 




Figure 23. Manual selection of glomerular boundary. (A) XY plane (en 
face) image showing top-down view of glomerulus transverse mid-section. 
Diameter (d) is defined as indicated by arrow. Lateral cross-section 
surface area is subsequently computed from the diameter. (B) XZ plane 
image showing side-view of glomerulus vertical cross-section. Height of 
glomerulus is defined as indicated by arrow. Image size: 294 × 278 μm.  
All 3D DOCT data were subsequently analyzed by computing cumulative 
Doppler volume and Doppler flow range parameters. The cumulative Doppler volume 
(CDV) was calculated by summing together the volume of segmented voxels within the 
glomerular volume containing DOCT signals that were above the background threshold 
as defined below in Equation 12, where V(x,y,z) is individual voxel volume. 

xyz
z)y,V(x, CDV        (12) 
The threshold value (|vz| = 0.05 mm/s) for computing CDV was set to slightly 
above the average DOCT signal from regions of static tissue. The CDV is not equivalent 
to “Blood Volume” as DOCT is only sensitive to scatterers (red blood cells). Therefore, 
the CDV we measured is expected to be smaller than actual “Blood Volume” and is 
coupled with the level of hematocrit. 
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Doppler flow range (DFR) was defined as the flow rate at 90% area under the 
curve (AUC) of the 3D flow histogram. The omission of the last 10% was to reduce 
variability from outliers in the histogram that would significantly alter the flow range 
determination. 3D flow histograms were calculated by integrating the DOCT signal over 
the lateral cross-section (en face) area of the segmented capillaries within the glomerular 
volume at each depth position (XY frame) for a single glomerulus and then sorting them 
according to a consistent bin size. Integration over the en face plane eliminates the angle-
dependent uncertainty of the Doppler velocity therefore providing an accurate 
quantitation of flow as defined in Equation 13 below.
75
 Doppler flow calculations were 
performed in en face images according to Equation 13, where vz(x,y,z) is the segmented 
DOCT velocity according to a threshold of 0.05 mm/s integrated over the xy segmented 
DOCT area.   

xy
dxdyzyx ),,(vFlow z  (13) 
A graphical representation of the cumulative Doppler volume and Doppler flow 




Figure 24. Flow chart describing CDV and Doppler flow calculations.  
The illustration in Figure 24 depicts selecting only one en face frame and details 
the quantitative computations for only a single group within that frame. However, in the 
data analysis, cumulative Doppler volume (CDV) and Doppler flow range (DFR) 
calculations were performed on all segmented groups in all frames that were within the 
glomerular volume. The glomerular volume region is defined as the space surrounded by 
the capsule of Bowman, which was manually selected for each data set in the lateral (xy) 
and cross-sectional (xz) dimensions. 
3.2.4. Statistical Analysis 
Data is given as mean ± standard deviation. One-way ANOVA test was 
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performed to evaluate sampling variance followed by Tukey‟s multiple comparison test 
with respect to the “baseline” values to determine statistical significance (p < 0.05 were 
considered significant). All histograms were computed using consistent bin size of 5×10
-6
 
μl/s and minimum threshold equal to 0.05 mm/s. 
3.3.Results 
After the rat left kidney was exposed beneath the microscope, several glomeruli 
were located by scanning the beam across the surface of the kidney. 3D data sets of 
glomeruli were acquired and stored for subsequent analysis. With PIP (picture-in-picture) 
mode enabling simultaneous OCT/DOCT on-screen viewing, we were able to see blood 
flow in each glomerulus in real time while scanning the surface of the kidney. 
OCT/DOCT fused images were constructed offline to verify the spatial correlation of the 
captured DOCT signal. OCT/DOCT imaging of kidney glomerulus revealed intra-




Figure 25. OCT and DOCT imaging of rat glomerulus. (A,D,G) OCT en 
face view of single glomerulus. (B,E,H) DOCT en face view of the same 
glomerulus. (C,F,I) Fused OCT/DOCT image showing spatial agreement 
between the OCT image and the corresponding DOCT image. The three 
images in each row correspond to the same imaging plane in depth. Depth 
(A-C) = 440 μm; (B-F) = 470 μm; (G-I) = 545 μm. Arrow in (H) identifies 
arteriole extending away from glomerular body. Image size: 325 × 278 
μm.  
Figure 25 shows images of three en face planes at different depths in a 
representative glomerulus: the top row is the upper region (A-C), the middle row is the 
middle region (B-F), and the bottom row is the lower region (G-I). Figure 25A,D,G show 
OCT intensity images revealing the kidney microstructure. Numerous uriniferous tubules 
(dark, pill-shaped features) can be seen surrounding the glomerulus, which is the circular 
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structure in the middle of the image surrounded by the dark, crescent shaped capsular 
space of Bowman. Figure 25B,E,H show corresponding DOCT images from the same 
plane depicting red blood cell velocity in numerous glomerular capillaries. As indicated 
by the colormap scale, red to yellow represents increasing velocity of blood flow in one 
direction while blue to cyan represents increasing velocity of blood flow in the opposite 
direction. Therefore, the mixture of these colors seen in the DOCT images demonstrates 
the varying velocities as well as the convoluted nature of blood flow through the 
glomerular capillaries. Figure 25C,F,I are the fused OCT/DOCT images demonstrating 
the spatial correlation of the DOCT signal within the glomerulus seen in the OCT images. 
Three-dimensional (3D) en face OCT/DOCT images sectioning through the entire 
glomerular volume can demonstrate the interwoven and tortuous nature of the glomerular 
capillary bed. DOCT is also able to reveal the vascular pole (where the blood 
enters/leaves the glomerulus) showing the afferent or efferent arteriole (Figure 25H, 
arrow). Note that this imaging information is not readily apparent in the corresponding 
OCT structure image. Figure 26A shows a top-down view of the complete 3D DOCT 
signal captured from the glomerulus in Figure 25 where the vascular pole with an 
arteriole connecting to the glomerular capillaries can be identified (arrow). Figure 26B 
offers a 3D perspective of the OCT/DOCT signal from the same glomerulus. The 
grayscale colormap represents the segmented OCT structural image showing the renal 
tubules and Bowman‟s space, and the red/blue colormap represents the DOCT signal. 
Beneath the broad, gray, umbrella-like structure (Bowman‟s space) is the glomerulus 
interior where numerous DOCT signals nest together representing the blood flow in 




Figure 26. (A) Top-down (vertical projection) view showing numerous 
clustered DOCT signals within the glomerulus representing red blood cell 
velocities. Image size: 325 × 278 μm. (B) Three-dimensional (3D) 
rendering of the 3D OCT/DOCT data set of the glomerulus in Figure 25 
reconstructed from a series of cross-sectional images. Grayscale colormap 
represents segmented kidney microstructures from OCT and red-blue 
colormap represents bi-directional blood velocity from DOCT. Volume 
size: 325 × 278 × 580 μm. 
In vivo DOCT imaging was performed during three separate physiological states: 
baseline, following injection of mannitol, and following injection of angiotensin II. 
Figure 27 shows representative glomeruli imaged under each condition. Baseline DOCT 
is depicted in Figure 27B with mannitol and angiotensin II in Figure 27D and Figure 27F, 
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respectively. The increase and decrease of the DOCT signal is readily visible following 
administration of mannitol and angiotensin II. Corresponding OCT images are presented 
in Figure 27A,C,E for identification of glomerular region in the DOCT images. These 
images represent three different glomeruli due to the fact that multiple glomeruli were 
scanned for each physiologic condition and it was not readily feasible to return to the 






Figure 27. Representative OCT and DOCT images (XZ) from 3 different 
physiological states. A-B) baseline, C-D) after mannitol, and E-F) after 
angiotensin II. Comparison among the images shows differences in the 
observed DOCT signal in different glomeruli under altered blood flow 
conditions. Image size: 294 × 278 μm. 
Analyzing the 3D data sets enabled quantitative evaluation of the DOCT signal 
within the glomerular region. By segmenting the DOCT velocity signal at each depth 
position (en face plane) according to a minimum background threshold (|vz| = 0.05 mm/s) 
and multiplying by the cross-sectional area of the segmented signal (as described in 
Figure 24), blood flow histograms of the 3D DOCT data sets were obtained. Figure 28A 
shows a representative baseline blood flow histogram from the 3D DOCT imaging with 
Figure 28B showing close up view of histogram base (region below dashed line). 
Similarly, Figure 28C-D shows a representative blood flow histogram after injection of 
mannitol solution and Figure 28E-F after injection of angiotensin II. Positive flow rates 
represent flow with a positive axial vector component (i.e. flowing upward) and negative 





Figure 28. Blood flow histogram comparison. (A-B) Baseline blood flow 
histogram. (C-D) Blood flow histogram following injection of mannitol. 
(E-F) Blood flow histogram following injection of angiotensinII. Each 
histogram represents a compilation of the segmented DOCT signal at 
every en face plane through the depth of the glomerulus. Plots on the 
lower row are close-up versions at the base of the histograms (below the 
dashed line) in the upper row. Each group (A-B), (C-D), and (E-F) 
represents different glomeruli imaged in the same rat. 
Following injection of mannitol, the histogram peak increased to 3 times higher 
than the baseline histogram peak. This histogram represents the observed changes in one 
glomerulus (not same glomerulus as baseline) depicting a significant increase in 
cumulative Doppler volume after administering mannitol (a mild vasodilator), but also, 
the maximum blood flow rate increased as noted by the wider range of flow rates (both 
positive and negative) as seen in Figure 28D (arrows) that are absent in the baseline 
histogram. Blood flow resulting after injection of angiotensin II (a vasoconstrictor) was 
also significantly affected. Figure 28E-F show flow rates only within one or two of the 
lowest histogram bins depicting a noticeable decrease of overall blood flow. While these 
three histograms demonstrate blood flow in three different glomeruli, the results reflect 
the overall type of changes observed in all the glomeruli imaged under each condition.    
Three-dimensional (3D) analysis of OCT and DOCT data sets was performed to 
extract the total glomerular volume (GV), Doppler flow range (DFR), and cumulative 
Doppler volume (CDV) for each glomeruli imaged. Figure 29 shows the computed GV, 
DFR, and CDV from one representative rat kidney. Figure 29A shows the glomerular 
volume from each of the 7 physiological states induced during the experiment. Even 
though slight increases and decreases in glomerular volume were noticed throughout the 
different physiological states, no significant change in glomerular volume was observed 
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during all data sets collected. Figure 29B-C shows the DFR and CDV values from the 7 
different physiological states in the same rat. For each state, an average of 3-4 glomeruli 
were analyzed. For each quantitative parameter, values for all glomeruli imaged during 
that physiological state were averaged and plotted with standard deviation.  
 
Figure 29. Analysis of in vivo DOCT imaging of rat glomeruli. (A) 
Glomerular Volume. (B) Doppler Flow Range. (C) Cumulative Doppler 
Volume. Each of these parameters was measured in multiple glomeruli 
under 7 separate conditions: baseline (n=3), following IV injection of 
mannitol (n=3), after the effects of mannitol diminished (n=4), following a 
second IV injection of mannitol (n=3), after the effects of mannitol 
diminished (n=3), following a third IV injection of mannitol (n=3), and 
finally following an IV injection of angiotensis II (n=6). Asterisk (*) 
indicates p < 0.05 compared to “baseline.” Labels: Mann=mannitol; 
Recov=recovery; Ang=angiotensin II. 
It is interesting to note that after both the first and second mannitol injection, the 
DFR and CDV values returned to near-baseline levels during the “recover” period 
indicating that the effects of the mannitol were wearing off (~15-20 minutes elapsed 
since injection). Shortly after administering the third mannitol injection to increase blood 
flow (10 min), angiotensin II was injected. This injection of angiotensin II reduced both 
DFR and CDV dramatically, well below the baseline level, even against the opposing 




Optical imaging using DOCT, a functional extension of OCT, is able to reveal 
single glomerular blood flow in vivo. It is important to note that all the observations were 
performed without introducing artifacts otherwise associated with penetrating the kidney 
(i.e., performed in a non-invasive fashion). Furthermore, DOCT requires no exogenous 
contrast agents like multi-photon fluorescence microscopy
108, 109, 135
 and confocal laser 
scanning microscopy
136
 and offers deeper tissue penetration than most optical microscopy 
techniques. Although DOCT can penetrate to a depth of about ~1-2 mm, monitoring renal 
microcirculation less than 500 μm below the kidney surface following renal 
transplantation has been reported to yield a promising predictive marker for post-
transplant graft function.
137
 An additional advantage of DOCT is that it can acquire 
numerous cross-sectional images in rapid succession yielding comprehensive 3D 
volumes of tissue. Such images can be used to determine the size, shape, and blood flow 
through glomeruli, thereby providing pathological information regarding glomerular 
disease. Fast imaging speed
138





 devices for imaging blood flow in various orientations and even deeper in 
solid tissue or in not easily assessable locations allows DOCT to perform quick, repetitive 
3D scans that can provide vital information for kidney evaluation. These unique aspects 
of DOCT might make this imaging technology useful in clinical settings.    
In our study, we demonstrated the ability of DOCT to quantitatively image 
glomerular blood flow in vivo. Blood cell velocities (between ±1 mm/s) obtained with 
DOCT agree well with previous optical imaging studies
101, 136





 μl/sec) as compared with values reported in the rat cerebral cortex.
75
 
However, DOCT quantifies velocity by detecting phase difference and therefore has an 
inherent phase-wrapping effect (since phase detection is limited by ). The maximum 
detectable velocity (without phase-wrapping) is determined by the axial scan speed
141
 and 
the minimum is based on the inherent phase noise present from the laser. In our system, 
16 kHz axial scan rate yields our upper detection limit of ~3.90 mm/s with minimum 
limit of ~0.05 mm/s, which encompasses reported values of intra-glomerular blood 
flow. However, when imaging blood flow in arterioles, phase wrapping effect might be 




One limitation involved in the DOCT signal segmentation is the fact that the 
intra-glomerular capillaries are at or below the axial resolution of our system and 
therefore speckle noise could be a significant factor that might affect quantification of the 
DOCT signal. Since the segmented DOCT signal is composed of numerous small DOCT 
clusters representing the small vessels within the glomerulus, a large number of the 
voxels are boundary voxels and thus may only represent partially filled voxels. Some of 
the partial voxel effects might be alleviated by de-speckling but all the values we reported 
were calculated directly from the raw segmented DOCT signal prior to any image 
processing. We did not pursue any correction method for the possible error accrued from 
incomplete voxels.  
Furthermore, if the vascular pattern is of more interest, other techniques such as 
Doppler variance imaging,
118
 speckle variance imaging,
142





 and optical microangiography (OMAG)
144
 can be applied. Future studies 
are also needed to cross-validate the blood flow measured by DOCT with confocal or 
two-photon microscopy by using multi-modal optical systems.
145-148
 
Characterization of the captured 3D Doppler signal within the glomerular volume 
by the CDV and DFR metrics can relate the Doppler magnitude and spatial volume 
observed in each glomerulus. While these two parameters are not sensitive to the same 
criteria, changes in capillary size/quantity and in flow speed will be detected by 
employing both in data analysis. For example, if the flow were to double while the 
capillaries remained the same size, the DFR would change accordingly but the CDV 
would remain constant. Likewise, if the number or size of the capillaries would change 
but the DFR did not, the CDV would indicate this change. By using both DFR and CDV 
metrics, alterations in the distribution (height or width) of the flow histogram can be 
detected and monitored for the 3D DOCT signal in each glomerulus. 
While the Munich-Wistar rat model provides superficial glomeruli that can be 
readily observed, the capability of DOCT to detect glomerular blood flow in the human 
kidney has yet to be demonstrated. Previous studies show the ability of OCT to image 
glomeruli in the intact human kidney ex vivo 
114, 115
 and several of the studies mentioned 
above report using optical imaging methods at depths much shallower than DOCT to 
monitor renal circulation in animal models and transplant patients. Therefore, future 
studies using DOCT to quantify microcirculation changes compared with immediate and 
long-term transplant outcome and compared with renal disease progression would 
provide needed insights regarding possible future clinical applications of DOCT. 
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However, the sensitivity of DOCT to detect subtle changes that can be associated with 
disease states (such as diabetes or renal artery stenosis) or with abnormal states (such as 
anemia or partial/full nephrectomy) has not yet been demonstrated.
149
 Thus, further 
studies are needed to evaluate native blood flow responses to renal disease in animal 
models and human patients in order to better understand the capability of OCT/DOCT to 
provide quantitative measurements of the kidney. 
3.5.Conclusion 
In these studies, using an OCT/DOCT system with ~12 μm axial resolution, ~2 
μm transverse resolution, and 16 kHz axial scan rate we have demonstrated three-
dimensional (3D), label-free imaging of microcirculation in the rat glomerulus in vivo 
under differing physiological conditions. After injection of mannitol, DFR increased to 
approximately 2 times baseline value and CDV increased to approximately 4 times 
baseline value. Then, after injection of angiotensin II, DFR and CDV decreased to less 
than 30% of baseline value. If larger bandwidth light sources are used, the axial 
resolution can be improved significantly and possibly resolving individual glomerular 
capillaries. Some studies report axial resolutions of ~2.5 μm
150
 and even down to 1 μm.
151
   
The ability of DOCT to visualize hemodynamic changes in vivo could provide a 
direct method for clinicians to evaluate kidney perfusion and response to therapy in real 
time. Furthermore, intraoperative visualization and analysis of alterations in renal 




4. OCT/DOCT Imaging of Human Kidney Transplant 
4.1.Introduction 
4.1.1. Kidney Injury 
Acute kidney injury (AKI) is a life threatening disease with a persistently high 
mortality and morbidity rate despite the advances in supportive care. AKI generally refers 
to an abrupt and sustained decrease of renal function resulting in retention of nitrogenous 
waste (urea and creatinine) in the blood and disrupted fluid and electrolyte 
homeostasis.
152-154
 It has been estimated that the incidence of intrinsic AKI is 
approximately 115,000 cases/year.
155
 AKI is typically diagnosed by observing rises in 
blood urea nitrogen (BUN) and serum creatinine (SCr).
55, 156, 157
 However, BUN-to-SCr 
ratio is a suboptimal indicator of renal function during AKI,
157
 and does not accurately 
reflect the degree of dysfunction until reaching a steady-state after several days.
158, 159
 
A majority of AKI (50%) is caused by ischemic injury to the kidney.
157
 Ischemia-
reperfusion injury is involved in both cadaver and live donor kidney transplantation 
procedures. AKI, due to ischemia-reperfusion, is known to occur frequently after kidney 
transplantation and often leads to varying degrees of early renal dysfunction.
160
 It is also 
known that 10-30% of AKI is caused by renal disorders.
156
  
Considering renal causes in terms of anatomic compartments is helpful for the 
differential diagnosis of AKI.
156
 AKI has distinct changes in both morphology (including 
loss of glomerular volume and tubular necrosis
161
) and function (including reduced blood 
flow and glomerular filtration rate
55, 156
). However, no objective tool currently exists in 
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clinics to rapidly detect the degree and extent of AKI, and consequently, therapeutic 
interventions are not able to be implemented effectively. 
Since the timing of interventions is critical to the potential success and outcome 
of a therapy, the capability of early diagnosis of AKI, quantification of disease extent and 
severity, and evaluation of the response to early treatments is of great importance for a 
successful therapy. Therefore, there is a critical need to develop new diagnostic tools to 
assess the extent of disease, quantify the physiological parameters of disease, and 
evaluate disease progression or response to therapy in vivo and in real time. Such a 
technology would have a significant impact on the clinical diagnosis and prognosis of 
AKI patients. 
4.1.2. Renal Blood Flow Imaging Modalities 
Renal blood flow (RBF) is able to be imaged in vivo by several different imaging 
modalities. One commonly performed imaging modality for measuring RBF in the clinic 
is a renogram also known as a nuclear medicine scan. In this imaging procedure, the 





 or technetium-99m linked to diethylene 




 and then continuously imaged by a 
gamma camera to obtain a time series of the isotope as it is filtered out of the blood in the 
kidney. This type of scan is performed for an extensive amount of time, usually ranging 
from 30 minutes to 1 hour. However, interpreting the results of the scan is rather 
straightforward. A longer residency time of the isotope in the kidney, which is measured 
as a stronger signal than lower residency times, is indicative of reduced renal blood flow 
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due to the extended collection of emitted radiation coming from the kidney. However, the 
drawback of this imaging procedure is the need to inject, not only an exogenous contrast 
agent, but one that releases ionizing radiation. This can pose serious health risks to the 
patient from prolonged exposure times that are dependent upon the ability of the patient 
to filter and excrete the isotope from their body. Also, the low resolution of this imaging 
procedure is really only able to quantify RBF on a whole organ scale, or perhaps 
regionally at best. 
A second imaging modality that can be used to measure RBF in the clinic but at a 
significantly higher cost is positron emission tomography (PET). RBF is measured by 
administering an IV injection of a radiotracer while the patient is in the PET imaging 
scanner. PET imaging of RBF is similar in principle to the nuclear medicine scan in that 
it captures a times series of the tracer as it is filtered out of the blood in the kidney. Like 
with nuclear medicine scans, PET imaging detects gamma rays, which result from 
positron emissions during the nuclear transformation of the tracer. Some of the 
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 Studies have 
demonstrated the ability of PET to quantify RBF in animal models
166-168
 as well as in 
humans.
86-90
 The resolution of PET imaging (~5 mm) is better than the performance of 
the nuclear medicine scan, allowing for more localized quantification of RBF. But, the 
use of an exogenous radioactive contrast agent still poses similar health risks to the 
patient as the nuclear medicine scan. 
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Thirdly, magnetic resonance imaging (MRI) is another imaging modality that has 
the capability to image RBF in two different ways. One way is dynamic contrast 
enhancement (DCE) MRI and the other is by arterial spin labeling (ASL) MRI. DCE 
MRI follows a similar regime as PET imaging described above where a bolus injection of 
a contrast agent is administered and a time series of the tracer is imaged as it is filtered 
out of the body in the kidney. Some contrast agents used in DCE MRI are Gd-DTPA, 
polyamidoamine dendrimers, and gadoteridol.
169, 170
 Studies have shown that using these 
contrast agents quantitative RBF measurements in animals
171-173
 as well as in humans
91-93
 
can be obtained.  
The other way to image RBF using MRI is through arterial spin-labeling (ASL). 
ASL MRI does not require an exogenous contrast agent in order to detect blood flow. By 
altering the magnetization of arterial blood water at a particular longitudinal plane 
compared to the magnetization of the surrounding tissue, ASL MRI can detects the 
magnetic decay of the arterial blood water with T1 against that of the surrounding tissue 
thereby utilizing an endogenous contrast agent rather than an exogenous one.
174
 RBF has 
been quantified using ASL MRI in animal
175, 176
 and in human
94
 studies. However, in 
order to accurately determine the perfusion rate of the magnetically labeled blood, the 
blood and tissue magnetic field values must be known or assumed, along with the 
labeling efficiency, and the arterial transit time. Two detriments in ASL MRI come about 
from the need to use high-magnetic fields: 1) RF pulses at 3.0 T have a wavelength that 
approaches the size of the human head presenting the risk for standing electrical waves 
where concentrated RF energy can cause hot spots to generate in the brain, and 2) the 
homogeneity of the main magnetic field is much lower at 3.0 T than at 1.5 T because the 
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higher field strength gives rise to banding in the image acquisition and labeling of 
slices.
177
 ASL also has the challenge of dealing with low signal-to-noise ratios and the 
complexity of flow quantification.
178, 179
  
Lastly, RBF can also be measured using ultrasound (US) imaging in two ways, 
just like MRI. The first method is by using contrast-enhancement (CE) US and the 
second is by using Doppler US. US generates cross-sectional, depth-resolved images by 
propagating high-frequency sound waves through tissue and then measuring the echo 
delay of those waves with a transducer that must be in contact with the surface. This time 
delay corresponds to the acoustic impedance of the medium and along with the intensity 
of the echoes, US can compute 3D characterizations of the sample medium. Measuring 
RBF using CE US is performed by giving a bolus injection of microbubbles and then 
destroying the microbubbles with high intensity pulses and then measuring the rate at 
which the microbubble contrast agent replenishes the imaged region. Studies using CE 
US to quantify RBF have been performed in animal models
180-182
 as well as in humans.
99, 
100
 Even though CE US uses microbubbles as a contrast agent, they are short lived (on the 
order of minutes). However, the microbubbles naturally degrade in the body without any 
toxic effects, which is a positive characteristic over other exogenous contrast agents. But, 
the necessity of using repetitive high mechanical index pulses to completely disrupt all 
the microbubbles currently residing in the kidney vasculature is likely to be poorly 
tolerated by some patients (who are often acutely unwell to begin with). This procedure is 
mildly complicated too by requiring successful destruction of the microbubbles followed 
by the capture of a time intensity curve to determine perfusion rate. In some of the 
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reported studies, completely destroying the microbubbles was sometimes challenging. 
The second way to image RBF using US is by using Doppler US. Doppler US 
functions by detecting the frequency shift in the ultrasound waves due to moving 
reflectors in the imaged medium. The moving reflectors which Doppler US measures in 
tissue are red blood cells passing beneath the surface through the vasculature. Blood 
velocity can be determined by comparing the incident ultrasound frequency with the 
reflected ultrasound frequency, which can then provide an indirect measure of blood 
flow. Doppler US can also detect whether the blood is moving toward or away from the 
pulse beam depending on whether the reflected wavelength is compressed or expanded. 
Using this technique, studies have been performed to quantify RBF in humans to monitor 
various forms of renal disease and renal hemodynamics.
95-98
 However, a recent study was 
performed comparing the accuracy of Doppler US with implanted laser Doppler flow 
probes, which are well-established devices to accurately measure blood flow invasively. 
The authors concluded that there are large variations in Doppler US agreement, and 
overall, according to the poor correlation with the measurements obtained from the flow 
probes, it has low accuracy with significant bias in quantifying RBF.
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The advantage of all the aforementioned imaging modalities is their ability to 
non-invasively image RBF with a wide field-of-view, allowing entire single- or dual-
kidney monitoring and evaluation. However, the previous imaging modalities (excluding 
US) are really limited by their cost, widespread availability, and difficulty to be used at 
the bedside or during surgery. CE US, though, is receiving significant attention in recent 
years as a possible post-operation imaging modality to monitor kidney perfusion non-
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invasively following renal procedures, such as transplantation. But, the drawback of 
exogenous contrast agents and the complexity of the imaging procedure, still make 
employing CE US in quantifying RBF a challenging feat for clinicians. Optical imaging 
techniques, though, that have higher resolutions and greater sensitivities could be a more 
feasible method for monitoring and evaluating RBF, especially in an intra-operative 
setting. 
4.1.3. Optical Imaging Techniques for Renal Monitoring and Evaluation  
Several optical imaging techniques have been employed to study the kidney. 
Studies using confocal
105-107
 and multi-photon microscopy
108-110
 have demonstrated the 
ability to image kidney structure and function on animal models, but the penetration 
depth has been limited to several hundreds of microns,
111
 and therefore, using these 
imaging modalities is difficult for human studies due to the capsule surrounding the 
human kidney which can be several hundred microns thick. Nevertheless, optical imaging 
techniques have higher resolution than other imaging modalities and therefore are able to 
image the kidney on the cellular level to provide a direct measurement of RBF and GFR, 
which other imaging modalities are limited by their resolution capability. A relatively 
new optical imaging modality that can provide cellular level imaging but with deeper 
penetration than confocal or multi-photon microscopy is optical coherence tomography 
(OCT). OCT can provide subsurface imaging of biological tissues with deeper 
penetration depth (1-2 mm), and therefore, it can function as an “optical biopsy” to image 
kidney structure and function with a field-of-view (FOV) comparable to that of standard 
excisional biopsy and histology.
23, 184, 185
 Subsurface imaging with OCT is similar to 
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ultrasound but has significantly higher resolution (5-10 times) than clinical US, providing 
depth-resolved imaging of tissue microstructure with micron-level resolution near that of 
histology. The advantage is that OCT imaging can be performed in real time without the 
removal of a tissue specimen for staining and subsequent histological analysis. OCT has 












among others. However, clinical OCT imaging of the kidney is a new and under-explored 
area with strong translational potential.  
In addition, OCT can detect blood flow in vivo using the Doppler effect just like 







 and gastrointestinal tract,
50, 71
 as well as other 
locations. Doppler OCT (DOCT) combines the ability of OCT to captured high-
resolution structural images with corresponding Doppler velocity maps that can be 
merged together to identify regions with moving reflectors, indicating blood flow. Thus, 
OCT/DOCT is a powerful tool that combines structural and functional imaging which 
could be used to evaluate kidney status in vivo and in real time following surgical 
procedures. 
4.2.Material and Methods 
4.2.1. OCT System Setup and Design 
A custom-built OCT system with a fiber-optic, hand-held probe was used in this 
study, enabling real-time, intra-operative OCT imaging during kidney transplant 
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procedures (see  
Figure 30). Briefly, the details of the OCT system used in this study consisted of a 
Fourier-domain OCT system with swept-source laser operating at 1310 nm center 
wavelength and 100 nm bandwidth with ~90 dB sensitivity. The OCT axial resolution 
was ~12 μm, and using a 4x objective (Thorlabs, NA=0.1) in the sample arm, a transverse 
resolution of ~15 μm was achieved as determined by resolution chart. Laser scanning 
(axial) frequency was 16 kHz enabling real-time 2D imaging. But, due to significant 
motion artifacts that naturally arise from using a hand-held scanner, in vivo 3D imaging 
data sets were not able to be captured during the surgery. OCT image pixel dimensions 
were as follows: 1024 [X] by 512 [Z], and associated 2D image scan dimensions were 





Figure 30. Schematic of hand-held OCT imaging probe for intra-operative 
kidney imaging. Axial and transverse resolution, imaging speed, field-of-
view, and sensitivity parameters are listed in the inset table on the bottom 
right. OCT system schematic abbreviations, FC: fiber coupler, PC: 
polarization controller, C: collimator, MZI: Mach-Zehnder interferometer 
(frequency clock), M: mirror, BD: balanced detector, DAQ: data 
acquisition board, DCG: dispersion compensating glasses, OBJ: objective, 
XY: galvanometer mirrors. 
Figure 31 shows a demonstration of the hand-held OCT imaging probe with a 
formalin-fixed human kidney ex vivo. The probe is gently placed on the surface of the 
kidney as depicted in Figure 31B. Applying only light pressure ensures that the 
subsurface kidney structure and blood flow are not significantly distorted or disrupted 
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during the imaging process.  
 
Figure 31. Demonstration of OCT handheld probe used in ex vivo and in 
vivo kidney transplant imaging. (A) Handheld probe is placed gently on 
the surface of an ex vivo fixed human kidney to reveal subsurface renal 
microstructures. (B) Close-up of the yellow box outlined in (A) showing 
further details of the OCT imaging with the handheld probe. Arrow 
indicates the imaging position of the hand-held probe on the surface of the 
kidney.  
The hand-held OCT imaging device was assembled on a portable cart that can be 
easily wheeled into and out of the operating room during kidney transplantation 
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procedures. Figure 32 shows the portable imaging system on the three-level utility cart 
that was used to house and transport the system in this study. The imaging system was 
equipped with two output monitors facing opposing directions. One monitor enabled us 
to visualize and record the data while the second monitor let the physicians visualize the 
imaging, which aided in helping situate the probe at the optimal focusing position. This is 
further exemplified below in Figure 33 that shows the operation of the hand-held imaging 
probe by the physician during the transplant procedure. 
 
Figure 32. Portable hand-held OCT imaging system setup for clinical 
imaging during kidney transplantation. Dual-monitor output allows for 
simultaneous viewing by the physicians for evaluation and probe 
positioning and for our team for data collection.  
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4.2.2. Transplant Patients and Data Collection 
Prior to engaging in this research, the protocol was approved by the Institutional 
Review Boards at both Georgetown University and the University of Maryland College 
Park. Patients scheduled to receive kidney transplant at Georgetown University Medical 
Center (Georgetown, Washington D.C.) were enrolled in this study between February and 
September 2011. Informed consent was obtained from all patients prior to imaging. A 
total of 8 patients enrolled in this study (2 female, mean donor age 53.67±8.76 yrs), and 
for each patient we imaged the kidney ex vivo prior to transplant and also following 
reperfusion in vivo. However, we were not able to collect data from the kidney ex vivo 
and in vivo in all patients due to technical complications. In total, we collected data from 
7 ex vivo kidneys and 7 in vivo kidneys. From this data bank, we compared 4 patients‟ in 
vivo imaging data with measurements from standard clinical biomarker serum creatinine, 
which is a conventional indicator for post-graft renal function. 
Following extraction of the kidney from the donor patient, the kidney was 
transferred to an ice bath solution prior to transferring it into the recipient. If adipose 
tissue was surrounding the kidney, the adipose was cut away from the kidney surface 
(part of the normal transplant procedure) exposing the kidney cortex. Next, the handheld 
OCT imaging probe was guided into a sterile sleeve and the sterilized lens and probe tip 
were secured onto the end of the probe by the physician‟s assistant.  
After properly assembling the OCT imaging probe, several regions of the ex vivo 
kidney surface were then scanned using the handheld imaging probe. The handheld 
imaging probe used in this study is shown above in Figure 31. Since there is no blood 
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flowing through the ex vivo kidney, only OCT structure images were recorded for the ex 
vivo portion of the transplant procedures. After macroscopically surveying the cortex of 
the ex vivo kidney, the sterile imaging probe was placed on the surgical instrument table 
for imaging after the transplant. When the kidney was re-perfused in the patient after 
grafting, the transplanted kidney was imaged again in vivo. While gently stabilizing the 
kidney against the patient‟s abdominal wall, the physician imaged the cortex of the 
transplanted kidney at numerous locations on the surface. For in vivo kidney imaging, the 
fringe data (the complex OCT signal including both magnitude and phase information) 
was recorded to enable DOCT processing and analysis. Figure 33 illustrates the OCT 
imaging system position next to the surgical table in the operating room and the 
utilization of the hand-held imaging probe by the physicians to visualize the kidney in 




Figure 33. Intra-operative OCT/DOCT imaging of kidney post-
reperfusion. The imaging system is kept several feet away from the 
operating table and only the handheld probe draped with a sterile sleeve is 
permitted to come into contact with bed and the patient. 
For both ex vivo and in vivo kidney imaging, OCT images were taken at random 
locations across the kidney cortex totaling several hundred cross-sectional images that 
were stored on computer to be analyzed offline after the procedure. As mentioned above, 
during both ex vivo and in vivo kidney imaging occasions, a separate monitor was 
provided for the physician to visualize the real-time OCT imaging of the kidney they 
were performing during the surgery while allowing us to be able to observe and record 
the data using an auxiliary monitor. 
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4.2.3. Image Analysis 
A subset of the recorded OCT/DOCT images that were in focus and free from 
significant motion artifacts (i.e. did not contain blurring from rapidly moving the probe) 
were exported from each patient for the in vivo portions of the transplantation procedure 
following reperfusion. A semi-quantitative analysis of the OCT/DOCT images was 
performed to evaluate the size/shape, density/uniformity, and blood flow observed.
189
 
Each category was scored according to the criteria listed below in Table 2. Scored values 
for the two tubule categories (tubule size/shape and tubule density/uniformity) were 
averaged and then the averaged value was added to the blood flow score for each patient 
to obtain an index value representing the overall status of the kidney. Thus, equal weight 
is given to the tubule and blood flow criteria in the scoring of the images. Example 
images of the tubule morphology for both the size/shape and the density/uniformity are 
provided in Figure 34. These images illustrate the visual appearance represented by the 
various scoring values and can be used as a training data set for standardizing the scoring 
















Data is insufficient 
to rank parameter 
Data is insufficient to 
rank parameter 
Data is insufficient 
to rank parameter 
1      
(poor) 
Tubules are closed 
Very sparse tubules or 
no tubules are visible 
Little to no blood 
flow was observed 
2 
(moderate) 
Tubules are visible 
but with slightly 
deformed shape or 
smaller size 
Tubule presence is 
heterogeneous or not 
consistently visible 
Only couple 
vessels with blood 
flow were 
observed 
3     
(good) 
Tubules are 
visible, open, and 
round  
Uniform tubules are 
visible throughout all 
regions imaged 
Numerous (>3) 








Figure 34. Examples of in vivo OCT images of human kidney depicting 
the scoring descriptions in Table 2 for tubule size/shape and tubule 
density/uniformity. Tubule size/shape: (A) poor (B) moderate (C) good. 
Tubule density/uniformity: (A) poor (B) moderate (C) good. Scale bar = 
500 μm.  
The image scoring results were then correlated with conventional biomarker 
measurements related to post-graft renal function. Image analysis results represent only a 
snap-shot of the kidney structure and function during the transplant procedure shortly 
after reperfusion. 
4.2.4. Evaluation of Post-Graft Function  
Post-operatively, serum creatinine (SCr) measurements were obtained daily for 
the first week after transplantation from Georgetown University Medical Center and were 
analyzed with standard clinical assays. SCr is a clinical “gold standard” parameter for 
evaluating renal graft function.
190
 SCr plots were constructed for patients with post-
transplant blood lab and in vivo imaging results. Comparison with pre-transplant SCr 
values was performed by plotting the relative change in SCr beginning on the day of the 
transplant. To compare post-transplant SCr with image analysis results, SCr at days 1 and 
8 were plotted against the index value for each patient. 
4.3.Results 
4.3.1. Ex Vivo Kidney Imaging 
OCT imaging was performed on donor kidneys while in ice bath prior to 
transplanting into the recipient. Excess perirenal fat was cut away as part of the normal 
procedure exposing the kidney surface for imaging. The donor kidney surface was 
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surveyed while soaking in the ice bath to globally assess the renal microstructures 
(tubules, vessels, and glomeruli). Figure 35 shows representative OCT structural imaging 
of the ex vivo kidney before transplantation. The kidney capsule is visible along with the 
renal parenchyma but, in general, the renal microstructures (e.g. renal tubules) were not 
visible. Occasionally a tubule, vessel, or glomerulus appeared but most of the ex vivo 
imaging data is similar to the example shown in Figure 35.  
 
Figure 35. Ex vivo OCT imaging of human donor kidney. Very few renal 
structures were visible below the capsule prior to transplantation. Data 
from patient #7. Scale bar = 500 μm. 
4.3.2. In Vivo Kidney Imaging 
Immediately following grafting of the donor kidney into the recipient and 
unclamping of the renal vessels, we performed OCT/DOCT imaging of the transplanted 
kidney within the abdominal cavity of the patient as illustrated above in Figure 33. Real 
time OCT structural imaging revealed numerous uriniferous tubules below the renal 





Figure 36. OCT imaging of in vivo human kidney showing open 
uriniferous tubules below the renal capsule. Tubules appear to be fairly 
open and round with some degree of homogeneity throughout the images. 




Figure 37. OCT imaging of in vivo human kidney showing uriniferous 
tubules below the renal capsule. Tubules appear to be very open and 
mostly round in shape and homogeneous throughout the images. Data 
from from patient #6. Scale bar = 500 μm.  
OCT fringe data was also recorded during in vivo imaging to enable DOCT 
imaging for visualizing blood flow in real time. Figure 38 demonstrates OCT/DOCT 
imaging of the transplant kidney in vivo. OCT is displayed in grayscale and DOCT is 
overlaid with a colormap. Blue-cyan represents blood flow in one direction while red-
yellow represent blood flow in the opposite direction. While several vessels are noticed in 
Figure 38A-D, no open tubules are observed around the vessels. Closed tubules indicate 




Figure 38. OCT/DOCT imaging of in vivo kidney. Blood flow is seen in 
numerous cortical vessels but uriniferous tubules appear to be closed and 
not visible in adjacent image regions. Patient #5. Scale bar = 500 μm. 
While surveying the kidney surface of patient #5 in vivo, several regions had 
closed tubules as noted above in Figure 38. However, as the hand-held imaging probe 
was moved to other parts of the kidney open tubules were readily visible. An example of 
the difference between regions with closed tubules and open tubules is shown below in 
Figure 39. Other regions of the kidney imaged in patient #5 showed visible open tubules 





Figure 39. OCT/DOCT imaging of in vivo human kidney showing 
regional variations in the openness of uriniferous tubules. (A) Tubules are 
closed and thus not visible, suggesting impaired renal function in this 
region. (B) Right side of image shows closed tubules again but left side 
reveals region with open tubules. Data from patient #5. Scale bar = 500 
μm. 
 
Figure 40. Additional OCT/DOCT imaging of in vivo human kidney 
showing regional variations in the openness of uriniferous tubules. (A) 
Open tubules can be seen below capsule. (B) Some regions display open 
tubules while others do not have open tubules. Data from patient #5. Scale 
bar = 500 μm. 
Figure 41 shows the combination of morphological imaging with OCT and 
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functional imaging with DOCT for one patient that displayed good tubular morphology 
and blood flow. Fairly densely packed uriniferous tubules are observed with several 
cortical blood vessels indicating perfusion. 
 
Figure 41. In vivo human kidney showing open tubules and cortical blood 
flow. Open tubules appear round and relatively uniform across all images. 
Also, a larger blood vessel is seen in (B) against some smaller vessels 
observed in (A,C,&D). Data from patient #3. Scale bar = 500 μm. 
The combination of OCT and DOCT for visualizing renal microstructures and 
blood flow can enable the assessment of renal function and possibly predict graft 
outcome. Based on these morphological and functional criteria, a semi-quantitative 
analysis was performed on six of the eight patients (two patients did not have sufficient in 
vivo data for the analysis). The results are summarized below in Table 3. Scoring values 
for tubule size/shape, density/uniformity, and observed blood flow in all in vivo 
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OCT/DOCT data sets are based on the defined criteria listed above in Table 2.  











1 Living N/A  N/A 
2 Living 2 2 2 4 
3 Living 3 3 2 5 
4 Living N/A N/A 
5 Living 2 2 3 5 
6 Living 3 3 1 4 
7 Living 2 2 1 2 
8 Living 2 2 1 2 
 
Lab results for daily creatinine levels from patients #2, #3, #5, & #6 (patients #1 
& #4 had insufficient imaging data and we currently do not have lab results for patients 
#7 & #8) are shown below in Figure 42. As a clinical parameter measuring post-graft 
renal function, serum creatinine is used to indicate the acceptance of the donor kidney 




Figure 42. Summary of serum creatinine values for the first post-operative 
week. (A) Serum creatinine values are plotted for 4 patients with 
OCT/DOCT in vivo imaging data (patients #2, #3, #5, & #6). (B) Percent 
change in serum creatinine from day 0. Measurements were taken daily for 
each patient for the first week following transplantation (excluding day 7 
for patients #2 and #3). For the remainder of the patients, the cause is due 
to either: 1) insufficient in vivo imaging data to correlate with biomarkers, 





The post-operative serum creatinine levels for the first week following transplant 
for patients #2, #3, #5, & #6 were then compared to the scoring results from the semi-
quantitative analysis in Table 3. Figure 43 shows the results of the correlation on post-
operative days 1 and 8. It can be noted that by day 8, 3 of 4 patients had reached near-
normal creatinine levels (horizontal dashed line). The outlier in Figure 43B is patient #6 
which displayed an increase in creatinine several days post-operatively before beginning 
to decrease on days 4-5 (see Figure 42).  
 
Figure 43. Correlation between serum creatinine at day 1 and day 8 post-
operative and the OCT/DOCT image scoring index. Horizontal dashed 
line indicates upper-limit of normal creatinine levels (~1.3 mg/dl). Data 
from patients #2, #3, #5, & #6. 
4.4.Discussion 
During transplantation every kidney undergoes a period of ischemic injury and 
then reperfusion due to the nature of transferring the kidney from the donor to the 
recipient. However, in light of this detriment, no pharmacologic interventions have been 
found that protect the kidney from this injury. Ischemia-reperfusion injury is known to 
cause tubular obstruction that decreases glomerular filtration rate and arteriolar 
vasoconstriction that disturbs glomerular blood flow.
191
 Tubular morphology has been 
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shown to be correlated with ischemia time in rabbit kidney transplant studies,
106, 192
 and 
also a recent study has demonstrated that renal microcirculation changes might be able to 
predict early renal graft dysfunction induced by ischemia-reperfusion injury.
137
  
This study demonstrates the feasibility of OCT/DOCT imaging of the human 
kidney during kidney transplantation. OCT/DOCT imaging results were scored according 
to morphological and functional characteristics as a diagnostic parameter to predict post-
graft renal function. The scoring index from the semi-quantitative imaging analysis was 
then compared with standard biomarker (serum creatinine) measurements that reflect 
post-graft renal function. However, this study is only an initial pilot study and has too 
few patient numbers to draw any definitive correlation between the imaging results and 
kidney graft function. The preliminary results of this study suggest that OCT/DOCT may 
be a useful tool in intra-operative monitoring and evaluation of the transplant kidney for 
predicting post-graft function after ischemia-reperfusion injury. 
One patient (#6) displayed a slight rise in serum creatinine (SCr) level following 
transplant until approximately day 4 when it began to decrease. This abnormal behavior 
could have been due to several causes. First, the transplanted kidney might have 
experienced some ischemia-reperfusion injury causing a brief delay in its functioning 
after transplant. However, this seems unlikely as the ischemia time for the living donor 
kidney is quite short (~1-2 hours). Second, acute rejection of the kidney sometimes 
results in delayed functioning of the kidney. Thirdly, certain medications (e.g. certain 
antibiotics) administered to the patient can cause elevated SCr even with a fully 
functioning kidney. However, the cause for the abnormal SCr of patient #6 has not yet 
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been established. Imaging results from patient #6 appeared to be quite good and were 
ranked as such in the semi-quantitative scoring analysis. Further background information 
on the post-transplant evaluation of the patient and any medical interventions are 
necessary in order to identify the cause for the delay in renal function. 
4.4.1. Critique of Methods 
We acknowledge that there are several limitations in this study. First, as already 
mentioned, the lack of patient numbers makes it challenging to determine the correlation 
between our optical imaging results and the post-graft function of the kidney. Higher 
patient numbers are necessary to determine the accuracy of using OCT/DOCT to predict 
post-graft outcome. Secondly, the semi-quantitative image analysis is not the most 
objective method for analyzing the imaging data. Computing the average tubular 
diameter and tubular volume ratio (ratio of tubular volume per volume of parenchyma) 
would be more objective measures to rank the morphological parameters of the OCT 
data. Performing 3D OCT/DOCT imaging would allow for more versatile metrics to be 
employed to quantify the image results, such as quantifying blood flow. However, image 
motion from the hand-held probe presently precludes 3D imaging. Better stabilization of 
the kidney within the patient‟s abdomen and securing the imaging probe to an articulating 
mechanical arm could dramatically reduce motion artifacts during in vivo imaging that 
would allow for 3D image volumes to be recorded. 
4.4.2. Future Direction 
Recent studies have shown a dramatic difference in renal microvascular blood 





 Since ischemic injury duration has already been correlated with post-graft function in 
rabbit studies using OCT, a clinical trial that investigates this technique in humans for 
living donors versus deceased donors would yield likely promising insights into the 
correlation between the duration of ischemic injury and post-graft function. The present 
study focused solely on living donors that had a relatively short duration of ischemic 
injury. We have demonstrated the ability of OCT to imaging living donor kidneys, 
therefore, the results suggest that it is a suitable image modality to investigate the longer 
ischemic times associated with deceased donors as well. 
Because deceased donor kidneys experience a longer duration of ischemia leading 
to varying degrees of delayed-graft function, they are at a higher risk for subsequent 
failure or rejection. Due to the shortage of kidneys for transplantation in relation to the 
large number of patients with terminal renal failure, there is an increase in the number of 
marginal kidneys that are being transplanted.
190
 At this time there is no objective tool to 
assess the status of donor kidneys or to predict the post-graft outcome of a donor kidney 
in the recipient. OCT‟s ability to reveal the subsurface renal microstructure could be used 
to assess donor kidney status and thereby predict the post-graft function of the kidney in 
the recipient. Pre-transplant assessment of donor kidney status is of benefit because it 
might indicate potential increased risk in marginal donor kidneys where the recipient 
could profit from additional interventions or treatment. However, further work is required 
to investigate the potential markers and correlation of renal microstructure with graft 
outcomes. And, in addition, further work is necessary to establish the efficacy of 
therapeutic maneuvers in cases with donor kidneys that might potentially present delay-
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graft function or other post-operative complications. 
4.5.Conclusion 
OCT is a powerful medical imaging technology that can reveal microstructure and 
blood flow in biological tissue in real time. Our preliminary results demonstrate the 
feasibility of using OCT to assess kidney status immediately following reperfusion by 
examining tubular morphology and density and renal blood flow in vivo.  
With ~12 μm axial and ~15 μm transverse resolution and 16 kHz axial scan rate, 
our OCT system revealed renal tubules and cortical blood vessels in real-time during 
transplantation procedures. Due to significant motion from the hand-held scanner, 3D 
OCT imaging was not able to be performed with our current image acquisition speed. 
However, this limitation could be solved by using faster laser sources with higher 
scanning rates. One study reported using an OCT system with axial scan rate of 370 kHz 
yielding sub-second 3D volume data set acquisition (~0.7 s).
194
 Furthermore, using novel 
laser sources, some studies report being able to perform scan rates reaching even 5 
MHz.
195, 196
 At this scan rate it would take only 52 ms to perform a 3D scan consisting of 
262144 axial scans (XY: 512×512). Higher scanning rates would decrease motion 
artifacts during image acquisition and also enable faster blood velocities to be detected 
with DOCT. 
Furthermore, by comparing a scoring index consisting of multiple imaging 
parameters with post-graft function, the diagnostic potential of OCT was investigated for 
the first time. All in vivo data sets yielded good quantitative results that correlated well 
with patient creatinine levels after 1 week post-transplant. However, our study requires 
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additional patient numbers to definitively identify any correlation with graft-outcome. In 
addition, improved diagnostic parameters with 3D imaging could better assist in 




5. OCT Imaging of Renal Cancer in Humans 
5.1.Introduction 
5.1.1. Renal Cancer 
Renal cancer is the 7
th
 leading malignant condition among men and 12
th
 among 
women in the United States and accounts for 3.8% of all cancers.
197
 The American 
Cancer Society estimates that approximately 60,920 (37,120 in men and 23,800 in 
women) new cases of renal cancer will present and 13,120 (8,270 men and 4,850 women) 
patients will die from this disease in the United States alone in 2011.
198
 Approximately 1 
in 67 people (1.49%) will develop renal cancer (prevalence) with the highest incidence in 
people over 55 years of age.
198
 The most common form of renal cancer is renal cell 
carcinoma (RCC) that arises from the epithelial lining of the uriniferous tubules and 
collecting ducts (~90%).
199
 The age-adjusted incidence of RCC has increased over the 
past 30 years at an annual rate of approximately 3%.
200, 201
 RCC consists of numerous 
subtypes of cancer including: clear cell, papillary, chromophobe, collecting duct, and 
unclassified. Other renal cancer types are: transitional cell, Wilms tumor, and renal 
sarcoma. However, there are also benign tumor types that arise such as renal adenoma, 
oncocytoma, and angiomyolipoma. Renal cancer displays distinct morphological changes 
on the microscopic level and eventually dramatic tissue re-organization on the 
macroscopic level allowing it to be stratified into various cell types and stages.
199
 
About 20-30% of newly diagnosed renal cancers have been found to be 
benign,
202-206
 and it is difficult to pre-operatively distinguish benign versus malignant 
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masses. Pre-operative biopsy and diagnosis of solid renal masses from radiographic 
images is variable due to inaccurate sampling, and permanent needle biopsy and CT have 
been reported to have 20% and 31% non-diagnostic rates, respectively.
202, 204, 207
 
Therefore, there is a need for an objective method that would improve the capability of 
differentiating benign from malignant renal tumors, thereby preventing unnecessary and 
potentially morbid surgical procedures. 
In addition, the incidence of renal cancer has increased with the identification of 
smaller renal masses (<4 cm) due to the advancement of pre-operative abdominal 




5.1.2. Renal Cancer Treatment 
For solid renal masses, nephron sparing procedures have been developed as an 
alternative to radial nephrectomy.
36
 Although highly effective, open surgery can be 
deleterious in elderly patients with multiple co-morbidities and increased surgical risks. 
Radical nephrectomy is not always necessary for small lesions, and thus, nephron sparing 
procedures such as partial nephrectomy and renal ablation are growing in popularity.
206
 
However, achieving a negative tumor margin is critical to ensuring the best oncological 
efficacy. 
Nephron sparing surgery is now established as the standard of care for small 
localized renal tumors
209, 210
 with excellent long-term survival reported using open 
surgery
211
 and laparoscopic techniques
212
. Tumor resectioning or ablation therapy 
(including cryo-ablation and radio-frequency ablation) have emerged as promising 
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treatment modalities for small renal tumors with encouraging short-term follow-up 
results.
213-216
 However, a main challenge of these minimally-invasive therapies is to 
accurately identify the tumor margin to preclude tumor recurrence. Currently, the 
standard of practice during nephron sparing procedures is to incorporate prior knowledge 
from radiographic images, ultrasound, and experience to determine the tumor area to 
ablate or resection. Therefore, an objective means of identifying a negative tumor margin 
still remains needed to assist the physician in determining the tissue margin surrounding 
the mass. The ability to accurately assess tumor morphology in real time to differentiate 
tumor from normal tissue and aid in optimal tumor treatment requires high-resolution 
imaging techniques where currently employed large field-of-view modalities and 
intraoperative ultrasound are insufficient.  
Over the last decade significant progress has been made in the area of non-
invasive or minimally-invasive imaging that has increased the sensitivity and specificity 
of renal cancer diagnosis. The reliable diagnosis of patients with renal neoplasms can 
provide physicians with the ability to develop patient-specific treatment options based on 
the malignant potential of the mass. Optical imaging techniques are suitable candidates 
that could improve diagnostic and therapeutic evaluation of renal masses intra-
operatively. 
5.1.3. OCT Imaging 
Optical imaging technologies have the potential to provide real-time, high-
resolution imaging of human tissue in vivo with resolutions near that of histopathology; 
therefore, it may significantly improve the clinicians‟ capability to accurately guide 
 98 
 
biopsies and correctly identify tumor margins intra-operatively. Confocal microscopy has 
been demonstrated to image kidney structure and function,
105-107
 but the penetration depth 
has been limited to several hundreds of microns. Optical coherence tomography (OCT) is 
another emerging biomedical imaging technology that can provide subsurface imaging of 
biological tissues, similar to ultrasound images, but with significantly higher resolution 
(5-10 times).
23, 184, 217
 OCT has deeper penetration depth than confocal microscopy (~1-2 
mm) and can function as a type of “optical biopsy” to enable visualization of tissue 




OCT can be readily interfaced with fiber-optic catheters, endoscopes, 
laparoscopes, and needle imaging probes to image inside the body.
38-40
 









 among others. 
These previous endoscopic studies demonstrated that OCT imaging could be readily 
integrated with standard endoscopic/laparoscopic procedures and provide valuable 
diagnostic information in situ and in real time. OCT guided biopsy has the potential to 
reduce sampling errors and improving surgical outcomes by accurately identifying tumor 
margins. The capability of OCT to visualize and quantify kidney structures in situ would 
be promising for differentiate the normal, benign, and malignant tissues. 
5.1.4. Previous Studies 
Pathologically, renal cancers exhibit distinct morphological differences compared 
to normal tissue, including architectural changes in the tubular diameter, volume, density, 
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and basic tissue organization and cell type. Standard histology can confirm cellular 
changes in tissue organization and cell type with resolutions at the single micron level. 
OCT has resolutions near that of histopathology but relies only on backscattered light for 
contrast. One previous study using an 890 nm OCT system investigated the ability of 
OCT to distinguish the appearance of normal and neoplastic (tumor) renal tissue ex vivo 
in human patients. By qualitatively comparing OCT images to that of conventional 
histology, differences in certain types of neoplastic tissues were able to be discerned 
while others were not able to be successfully differentiated. The authors concluded that 
transition cell carcinoma (TCC) and angiomyolipoma (AML) displayed unique 
identifiable features from normal parenchyma, but oncocytomas and other renal 
carcinoma subtypes  (papillary and chromophobe) differed only subtly from normal renal 
parenchyma in the OCT images.
218
 Therefore, due to a general heterogenous appearance 
in the OCT images of normal parenchyma and most renal cancer types (excluding TCC 
and AML), reliable differentiation was limited.  
It is also known that malignant renal tissues exhibit larger and irregularly shaped 
nuclei compared to that of normal tissue lending to an increase in the nuclear-to-
cytoplasm ratio.
219-221
 Changes in nuclei/cytoplasm ratio will affect the optical properties 
of the tissue by the index of refraction mismatch. This cellular transformation in 
malignant tissue suggests that there may be a discernable difference in the optical 
signature from normal versus tumor tissue. Previous studies using optical reflectance 
spectroscopy have established that there are different light scattering properties between 
tumor and normal renal tissue and even between malignant and benign tumor tissue.
222-224
 
Based on diffuse reflectance measurements, the spectra between normal and tumor renal 
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tissue diverges continuously with respect to wavelength between 600-900 nm. These 
studies indicate that there is a discernible difference in optical signatures that can be 
detected between normal renal tissue and tumor tissue. 
Tissue optical properties can also be estimated from the OCT axial profile (A-
scan).
225
 Recently, one group performed a study using OCT A-scans of human renal 
tissue ex vivo to extract the attenuation coefficient (μt = scattering, μs + absorption, μa) of 
normal and malignant renal tissue to quantitatively measure tissue optical properties. 
While an overall comparison of all their data yielded a significant difference between 
normal parenchyma and RCC tissue, a significant difference was not observed comparing 
each patient individually.
226
 Our results build off of this study by including addition 
patient data with improved imaging penetration. We hypothesize that there will be a 
significant difference in the attenuation coefficient measured with OCT between normal 
and tumor renal tissue. 
5.2.Materials and Methods 
5.2.1. Renal Specimen 
The protocol used in this study was approved by the Institutional Review Boards 
at both University of Maryland Baltimore campus as well as University of Maryland 
College Park campus. Patients that were scheduled for removal of suspicious renal mass 
underwent partial or complete nephrectomy at the University of Maryland Baltimore 
Medical Center (Baltimore, MD) were enrolled in this study between June and November 
2011. Informed consent was obtained from all patients prior to imaging.  A total of 9 
patients participated in this study (4 laparoscopic partial nephrectomies and 5 radical 
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nephrectomies). One patient included in this study had cancer arising from the collecting 
duct (urothelium) instead of from renal cell. In total, we collected data from 17 specimens 
(8 normal parenchyma and 9 tumors). For one patient, no normal parenchyma could be 
identified apart from the invasive tumor that nearly constituted the entire kidney. 
Therefore, only a tumor specimen was retrieved and imaged for that patient. When the 
imaging was completed after the surgery, each specimen was then stored in a clean 
container and sent to pathology for evaluation. 
5.2.2. Sample Preparation 
Immediately after surgical excision of the renal mass, the specimen was placed in 
holder and placed on separate examination table. If adipose tissue was surrounding the 
kidney, the adipose was gently cut away and a portion of the kidney cortex at the tumor 
site and at a normal region was exposed for imaging. Upon finishing exposing the kidney 
surface, a random macroscopic region (~1 cm
2
) representative of the renal mass was 
selected upon visual inspection by the surgeon followed by the selection of a random 
macroscopic region (~1 cm
2
) representative of normal parenchyma. Residual blood was 
rinsed away from the surface with saline solution and the specimen was then placed 
beneath the OCT microscope with the selected regions positioned appropriately for 
capturing 3D imaging of the site. No alteration or cutting of the specimen was performed 
after removal from the patient. 
5.2.3. Data Collection 
The details of the OCT system used in this study have been described 
previously.
114
 Briefly, a Fourier-domain OCT system with swept-source laser operating at 
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1310 nm center wavelength and 100 nm bandwidth was used in this study. The OCT 
axial resolution was ~12 μm, and using a 4x objective (Thorlabs, Inc., NA=0.1) in the 
sample arm, a transverse resolution of ~15 μm was achieved as determined by USAF 
resolution chart. Laser sweep rate was 16 kHz enabling rapid 2D and 3D imaging. 3D 
data set voxel sizes were as follows: 1024 [X] by 512 [Y] by 512 [Z]; associated 3D data 
set dimensions were 8 mm [X] by 9 mm [Y] by 2 mm [Z].    
Images were taken at 2 standard locations per specimen in situ (see Figure 44 for 
partial and radical nephrectomy diagrams). 3D data sets were recorded for each 
representative location totaling several hundred cross-sectional 2D OCT images that were 
stored on computer to be analyzed offline at a later date. Some specimens allowed for 
more than or fewer than 3 samples per tissue type, but overall, an average of 6 samples 
were taken from normal and tumor tissue (3 from each type) in all patients (excluding 1 




Figure 44. Location of OCT imaging during both (A) radical and (B) 
partial nephrectomy. Sites #1 – #3 are on the surface of the tumor while 
sites #4 – #6 are on the surface of normal parenchyma in regions where 
there is no peritumoral adipose tissue covering the capsule. 
5.2.4. Image Analysis 
A subset of raw OCT intensity images were exported from each patient for both 
tumor and normal tissue and analyzed using custom image analysis software written in 
Matlab (Mathworks, Natick, MA, USA). OCT images were selected based on minimal 
surface reflection to decrease the incident of image artifacts from detector saturation. 
Within selected images, axial scans free of artifacts, large vessels or other structures, and 
excessive shadowing were chosen for analysis. The backscattered-light intensity 
attenuation coefficient (μt) of each axial scan was determined using a modified-single 





 The attenuation coefficient can be calculated from the modified-single 
























where i is the axial OCT signal, z is the depth position, zcf is the confocal gate focal 
position, zR is the „apparent‟ Rayleigh length used to characterize the point spread 
function (PSF). If a renal capsule was present in the OCT image, the attenuation 
coefficient was measured beginning below the capsule. Also, areas with low surface 
reflection and detector saturation artifacts were selected for calculating the attenuation 
coefficient of the tissue. 
5.2.5. Pathological Evaluation 
Standard pathological report was considered to be the gold standard for verifying 
tumor and normal tissue from kidney specimens. A summary of the pathological 








Table 4. Patient demographical and pathological data. 
Number of patients 9 
Mean patient age (years) 52.1 
Male:female 6:3 
Patients with tumor and normal kidney tissue 8 
Patients with only tumor tissue 1 
  
Pathology diagnosis:  
RCC, clear cell 4 
MF RCC, papillary + clear cell 1 
Papillary 1 
Transitional cell 1 
Angiomyolipoma 1 
Oncocytoma 1 
*RCC = renal cell carcinoma 
*MF = multifocal 
 
 
5.2.6. Statistical Analysis 
Comparisons were made among the patient diagnoses in cooperation with a 
certified pathologist that was blinded to the selected regions of the kidney that were 
imaged. From the OCT data analysis, comparisons between the attenuation coefficient in 
tumor and normal kidney tissue were performed across all patients, treating each tissue 
type (normal or tumor) in each patient as a cluster of dependent observations related to 
each other). All attenuation coefficient (μt) values are reported as mean ± standard error. 
All data collected were analyzed with SAS software (SAS Institute Inc., Cary, 
NC, USA). Data comparison across all patients was performed using a linear mixed 
effects model to analyze statistical significance between normal renal tissue and tumor 
tissue among the cohort. The linear mixed effects model takes into account data where 
observations are not independent and compensates for the continuous dependence of 
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random effects, hierarchical effects, and effects found in repeated measures. From the 
linear mixed effects model, a p value < 0.05 from the statistical test was considered to be 
significant.  
5.3.Results 
A total of 17 specimens (8 normal parenchyma and 9 tumors) from 9 patients 
were imaged with OCT during this study. One patient had renal cancer arising from the 
collecting duct instead of having a renal cortical mass. Both benign (oncocytomas and 
angiomyolipomas) and malignant tumors (all other tumor types listed in Table 4) were 
evaluated for their optical attenuation patterns against normal renal parenchyma. An 
example of normal parenchyma and tumor tissue is displayed in Figure 45 with 
representative axial profiles from each comparing the optical attenuation between the two 
tissue types. Furthermore, Figure 45 also shows an example histogram of the attenuation 
coefficients obtained for both normal and tumor tissue types. While a separation can be 
seen between the attenuation coefficient for normal versus tumor tissue, other regions in 
from this patient did not exhibit such a distinct difference. This pattern of inter-region 




Figure 45. Representative OCT images and axial profiles for renal tissue 
from (A) normal and (B) tumor regions. Plot (C) displays axial profiles 
from the vertical dashed lines in (A) & (B) with the tissue surface 
positions aligned for easier comparison. The attenuation coefficients (μt) 
for normal and tumor tissue types using a modified single exponential 
decay model were 4.29 mm
-1
 and 2.96 mm
-1
, respectively. Renal capsule 
is apparent in the normal tissue (A) but not in tumor tissue (B). 
Attenuation fitting was taken from below the capsule and at a similar 
depth in tumor as indicated by the dashed lines of the model fit seen in 
(C). (D) Attenuation coefficient histogram of normal and tumor tissue 
showing the distribution of the attenuation coefficient in both regions. 
Data from Patient #2. Scale bar = 500 μm. 
 Upon visual inspection of the OCT images from normal and tumor tissue in all 
patients, differences in tissue features and patterns can be discerned in most patients (see 
Figure 46). However, some patients exhibited similar tissue appearance between normal 




Figure 46. Representative OCT images from normal and tumor regions 
for all patients (excluding patient #7 with only tumor tissue). Variations 
between normal and tumor tissue can be observed in majority of patients. 
However, variations even in the normal tissue can be seen among all the 
patients. Scale bar = 500 μm. 
 Since multiple locations on normal and tumor tissue were imaged in 3D, a 
large amount of axial scan attenuation coefficients were computed for each patient. To 
accommodate for the high number of attenuation coefficients, each 3D data set was 
divided into ~10 sections and the attenuation coefficients were then averaged within each 
section. This yielded ~60 attenuation coefficients for each patient from the ~6 regions 
that were imaged (~2-3 normal and ~2-3 tumor). The mean attenuation coefficient (μt) ± 
standard deviation for each patient as well as the overall comparison between the two 
tissue types is given below in Figure 47. From 23 normal kidney regions in 8 patients 
yielded an average attenuation coefficient of 4.41±0.74 mm
-1
, and from 26 tumor regions 
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in 9 patients yielded an average attenuation coefficient of 4.32±1.26 mm
-1
 (see Figure 
47B). The corresponding patient-specific pathological diagnosis is listed in Table 5. Four 
patients had RCC clear cell type, one patient had transitional cell carcinoma, one had 
RCC papillary type, and another had multifocal RCC with combined papillary and clear 






Figure 47. Quantitative OCT imaging analysis results. (A) Attenuation 
coefficient (μt) for normal and tumor tissue for each patient (excluding 
patient #7 which had only tumor tissue). Number of regions imaged per 
type of tissue for each patient is as follows (normal, tumor): patient #1 
(n=2, n=2), patient #2 (n=3, n=3), patient #3 (n=4, n=5), patient #4 (n=2, 
n=2), patient #5 (n=1, n=2), patient #6 (n=5, n=3), patient #8 (n=2, n=2), 
patient #9 (n=2, n=3). (B) Overall comparison between normal and tumor 
tissue across all regions of each tissue type from each patient (normal, 
n=23; tumor, n=26). 
Table 5. Patient-specific pathological diagnoses from Figure 47. 
Patient # Pathology 
1 Angiomyolipoma 
2 RCC, clear cell 
3 RCC, clear cell 
4 Oncocytoma 
5 RCC, clear cell 
6 Transitional cell carcinoma 
7 MF RCC, papillary + clear cell 
8 RCC, clear cell 
9 RCC, papillary 
 * RCC = renal cell carcinoma 
* MF = multifocal 
 
Across all 8 patients, a linear mixed effects model analysis was performed on the 
attenuation measurements from the comparison between normal (n=281) and tumor 
(n=348) tissue. The statistical significance of the analysis was determined to be p = 
0.2718.  
5.4.Discussion 
High-resolution, 3D imaging data sets of human kidney ex vivo were acquired 
using OCT for investigation of the optical properties of renal tumor tissue against normal 
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renal tissue. OCT is already an established medical imaging technology in 
ophthalmology
228






OCT provides cross-sectional images of optical backscattering with resolutions at 
~12 μm that can enable non-invasive of tissue morphology. This sort of “optical biopsy” 
can allow repeated sampling of tissue in situ. In many medical fields, OCT has become a 

















, among others. However, only two 
published studies to date have investigated OCT in detecting renal neoplasms.  
One study focused on distinguishing renal neoplasms from normal parenchyma 
based on characteristic architectural features seen in histology using an 800 nm OCT 
system. The authors concluded that certain types of neoplasms (aniomyolipoma and 
transitional cell carcinoma) exhibited distinct morphologic elements allowing them to be 
discerned from normal tissue while identification of other neoplasms (oncocytoma and 
various RCC subtypes) was more unreliable.
218
   
Another group investigated using the characteristic of optical attenuation in tissue 
from the OCT axial scan to distinguish renal cancer from normal parenchyma. The 
authors reported no significant difference (p=0.069) between normal and cancer tissue 
within each patient, but collectively across all patients, they found a significant difference 
(p=0.03) between renal cancer and normal parenchyma.
226
 Overall, the authors observed 
a higher optical attenuation coefficient in renal cancer tissue than in normal tissue when 
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same tissue types were all grouped together.  
In contrast to this, our results show, in general, a lower attenuation for renal tumor 
tissue compared with normal renal tissue (see Figure 47). Only two patients exhibited 
higher attenuation in tumor over normal tissue. However, our estimation of normal renal 
attenuation µt (~5 mm
-1
) is agreeable with their results of normal parenchyma. While we 
had the same sample size (n=8) and optical attenuation model as the previous study, our 
study includes samples from patients with benign tumors and non-RCC tumors while the 
former study selective focused on comparisons between normal and RCC tissue. We also 
observed high variation between normal and tumor tissue across all patients but found no 
statistical significance between their attenuation coefficients (p=0.2718).  
As seen in Figure 45, our OCT image penetration depth was ~0.8 mm for normal 
and ~1.2 mm for tumor. The depth of penetration improvement in tumor tissue 
substantiates the lower attenuation coefficients noted in Figure 47. However, these results 
did not match our expectation according to the larger and irregularly shaped nuclei that 
are known to characterize malignant renal tissue compared to normal parenchyma. These 
cellular changes are thought to give rise to an increase in refractive index mismatch and 
thus a higher attenuation coefficient. 
In our study, six out of eight patients with both normal and tumor tissue showed a 
lower attenuation coefficient in the tumor tissue than normal parenchyma. Two patients 
displayed the opposite trend, i.e., higher tumor attenuation than normal. One patient with 
significantly higher tumor tissue attenuation was diagnosed with transitional cell 
carcinoma, which is a renal malignancy that arises from the urothelial cells lining in the 
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renal calyces, collecting duct, and ureter. With the small sample size in this study it is 
difficult to draw any conclusions on the observed variance in optical attenuation values. It 
may be that differences in architectural changes that are associated with certain renal 
malignancies account for such inconsistencies in optical properties. However, more 
specimens are needed and then comparisons within each category of tumor type might 
reveal optical characteristics unique to classes of renal neoplasms.  
This study contains several limitations in its scope. First, all images were recorded 
ex vivo with no blood perfusion and collapsed renal microstructures like uriniferous 
tubules and glomeruli. Therefore, since this experimental condition is drastically different 
from in the living kidney, determining the attenuation coefficient in vivo may pose certain 
challenges. Primarily, the quantification of tissue attenuation from the axial profile may 
encounter artifacts due to the hollow tissue structures, such as renal tubules that are 
abundant throughout the superficial cortical layer. For accurate quantification of the 
attenuation coefficient from OCT images, image processing algorithms that remove the 
large fluctuations caused by these structures from the axial profile will need to be 
employed to compensate for regions of the tissue that are optically translucent. This will 
improve the quantification accuracy and reduce variability in fitting the attenuation 
model. 
In addition, we are using a modified single exponential decay model that takes 
into account the confocal gate and beam profile to fit the optical attenuation in the tissue. 
The modified single scattering model is an improved model over the simple single 
exponential decay which has been widely used by other research groups to quantitatively 
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differentiate normal and abnormal breast tissues
242
 and oral cancers.
243, 244
 But, more 
complicated attenuation decay models that incorporate multiple scattering effects can also 
be utilized to improve the accuracy of the optical attenuation fitting.
245
 Furthermore, 
alternative image processing and quantification algorithms can be employed to extract 
additional metrics from OCT images that could be used as diagnostic markers. Joint 
spatial frequency
246
 and texture image analysis methods, which are sensitive to tissue 
architectural features as well as the smoothness, coarseness, and regularity of speckle 
patterns
247, 248
, that have been shown to distinguish normal and cancerous tissues could be 
beneficial in detecting renal neoplasms as well. Along with additional image 
quantification algorithms, improved axial resolution to ~5 μm has been reported to 
enhance detection of upper gastrointestinal tract cancer with spatial frequency analysis 
and statistical texture analysis methods.
249
 
While this pilot feasibility study (like the other associated reports mentioned 
above) needs larger samples to confirm the findings, these preliminary results suggest 
that OCT as a diagnostic tool for identifying tumor from normal renal tissue is unclear. 
With mixed conclusions among the published literature, distinguishing neoplastic 
changes in renal tissue using OCT may require improved image processing or 
quantification metrics to ultimately differentiate between tumor and normal tissue in the 
kidney. 
If OCT is to be used in the clinic as an adjunct technology for assessing renal 
tumor margins intra-operatively, future studies will need to investigate the predictive 
value of the metric (or combination of metrics) that best establishes the cut-off values 
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between tumor and normal renal tissue. Also, if OCT is found to be a useful tool in the 
clinic during partial nephrectomy procedures, needle-based OCT probes may play an 
important role in aiding or replacing percutaneous needle biopsy. Imaging guidance could 
improve sampling error, or “optical biopsy” techniques may allow for more 
comprehensive assessment by not requiring tissue damage or excision. 
5.5.Conclusions 
With a ~12 μm axial and ~15 μm transverse resolution OCT system, we imaged 
multiple regions of both normal and tumor tissue from patients with renal masses. Based 
on the attenuation coefficients we extracted from both normal (4.41±0.74 mm
-1
, 8 
patients) and tumor (4.32±1.26 mm
-1
, 9 patients) renal tissue in ex vivo specimens, we 
conclude that optical attenuation coefficient may not be a sensitive enough diagnostic 
parameter to distinguish renal neoplasms tissue from normal tissue. However, in 
conjunction with previous studies, a larger number of patient samples are necessary 
before reaching a more definitive conclusion on whether optical attenuation using OCT is 
a suitable diagnostic method for detecting renal neoplasms.  
Furthermore, since qualitative differences can be observed between normal and 
tumor tissue in a majority of the patients, other quantitative parameters and image 
processing and analysis techniques may be able to better distinguish the two tissue types. 
In addition, a semi-automatic, computer-aided diagnostic algorithm may be more 
advantageous than a fully-automated method by allowing for physician input in 




6.1.Summary and Impact of Work 
The research described in this thesis includes one animal study and two human 
studies using OCT imaging technology as a diagnostic tool for medical imaging. The 
animal study and one human study deal with in vivo imaging while the second human 
study surveys ex vivo specimens only. Each component of this work will be summarized 
below in more detail. 
The first component of this research entailed in vivo imaging of the living rat 
kidney to quantify renal blood flow. 3D OCT/DOCT imaging data sets revealed single 
glomerular blood flow of the capillary tufts within Bowman‟s space. 3D quantification 
parameters cumulative Doppler volume (CDV) and Doppler flow range (DFR) reflected 
pharmacologically-induced changes in renal blood flow for both increased and decreased 
flow rates. Glomerular arterioles (afferent/efferent) were visible in some data sets but 
absolute glomerular blood flow was not able to be determined. This work demonstrates 
the feasibility of quantifying glomerular blood flow in vivo and would be useful for 
studying specific renal disease models or for imaging glomerular blood flow of the 
human kidney during surgery. Since OCT/DOCT imaging depth is much deeper and with 
higher resolution than other imaging modalities, it may prove highly useful for studying 
disease progression longitudinally within the same animal because it can reveal 
subsurface structure and function significantly deeper than conventional microscopy 
techniques, and it can be miniaturized into small probes for minimally-invasive imaging.   
The second component of this thesis is closely connected to the first in that we 
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translated OCT/DOCT imaging technology into the clinic to image the human kidney 
during transplantation procedures. Morphological and functional imaging of the human 
kidney in vivo was demonstrated using OCT/DOCT on the living human kidney 
following reperfusion. OCT structural imaging revealed uriniferous tubules within the 
renal parenchyma and DOCT revealed blood flow (both in cortical vessels and 
glomeruli). Imaging results were correlated with standard biomarkers (blood urea 
nitrogen and serum creatinine) using a semi-quantitative numerical scoring system. 
Ranking the OCT/DOCT imaging results and then comparing with post-graft function 
markers yielded insights into the usefulness of OCT/DOCT for evaluating kidney status 
after transplantation. With the small number of patients in this study, we demonstrated 
that renal tubules and blood flow can be visualized in real time immediately following 
reperfusion and that these parameters may help predict post-transplant renal function. 
In the third section of this work we investigated the feasibility of OCT to 
distinguish tumor renal tissue from normal parenchyma in human kidney specimens ex 
vivo. Using a modified single exponential decay model for fitting the OCT axial scan 
attenuation, average attenuation coefficients of tumor and normal tissue were compared. 
When the two tissue types (i.e. normal versus tumor) were compared across all patients, 
the results were found to be not statistically significant. These results stand in contrast to 
a former report that found a significant difference between renal cancer tissue and normal 
tissue with a similar sample size. This work shows that a higher number of patient 
samples are required to come to a definitive conclusion about using the attenuation 
coefficient from OCT images as a diagnostic marker to identify tumor tissue apart from 
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normal tissue in the kidney.  
6.2.Future Work 
Given the research discussed in this thesis, several further studies and 
improvements can be proposed for future work. For demonstrating in vivo imaging of 
glomerular blood flow in animal models using OCT/DOCT, a full-scale study of a 
particular renal disease progression for patient-specific management would naturally 
ensue. Chronic kidney disease (CKD) is one renal disease that is known to have changes 
in renal morphology (tubular atrophy, glomerulosclerosis, interstitial fibrosis) and 
function (altered renal hemodynamics). OCT/DOCT may be a suitable technology for 
identifying and quantifying changes in these parameters that are associated with CKD 
progression. Since OCT intensity images can reveal the size, shape, and density of 
uriniferous tubules, and the size and shape of glomeruli, and since DOCT can reveal renal 
cortical and glomerular blood flow, OCT/DOCT imaging appears to be an excellent 
technological candidate for determining the stage of CKD and monitoring its progression. 
Regarding the second component of this thesis, OCT/DOCT imaging of human 
kidney transplant to predict post-transplant graft function is an area of research that 
requires higher patient numbers to validate the sensitivity and specificity of the 
technique. Along with the continued in vivo OCT/DOCT imaging, 3D in vivo imaging 
could greatly assist in providing additional quantitative metrics for evaluating renal 
function. Quantitative metrics like glomerular blood flow and tubular volume ratio 
(tubule volume per volume of parenchyma) could prove to help physicians better 
understand the transplant kidney function soon after reperfusion rather than waiting hours 
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to days to receive urine and serum lab results that require time following the procedure to 
stabilize and become reliable measures.  
In addition, an untapped research area associated with kidney transplantation is 
evaluating the status of donor kidneys, especially donor kidneys from heart beating 
cadavers. Unlike living donor kidneys that are transplanted into the recipient within a 
relatively short period of time after harvesting, cadaver kidneys are stored for multiple 
hours before being transplanted into the recipient. During this time the ischemic insult to 
the kidney eventually causes the cells to die and the organ to cease being viable for 
transplantation. However, at the present time there is no objective method to assess the 
status of these cadaver kidneys beyond judging their status based on the elapsed time 
since harvesting. OCT intensity imaging may provide an objective means whereby the 
physician can visualize the internal microstructure of the donor kidney to evaluate its 
status prior to its transplantation thereby replacing the need to have to rely on a highly 
variable criterion, such as the duration of ischemia. Knowing the status of the kidney 
based on its microstructure could be an avenue that opens the door for the assessment of a 
larger pool of donor kidneys that otherwise might not be available. OCT might also be 
able to help prevent kidneys that are in poor condition from being transplanted and 
undergo post-graft failure. 
In the third component of this research, the most pressing future work appears to 
be the need to collect a higher number of samples to more rigidly test whether the 
attenuation coefficient is or is not a reliable metric for distinguishing tumor tissue from 
normal tissue in the kidney. With the high variability seen in our data and in other 
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published reports, it is possible that the attenuation coefficient may not be the best suited 
metric for characterizing renal neoplasms. Future work on this project could consist of 
developing more sensitive measures of the optical properties of renal tissue that can 
differentiate tumor from normal tissue. This may consist of more complicated optical 
attenuation models, or new optical or image analysis parameters. These options will need 
to be investigated before determining the ability of OCT in detecting renal neoplasms. 
Also, a natural extension of the ex vivo tissue analysis is to conduct an in vivo 
pilot feasibility study using a laparoscopic OCT imaging probe. In vivo conditions of the 
kidney differ considerably from ex vivo due to changes in the tissue morphology and 
perfusion when removed from the body. Intra-operative OCT imaging of the kidney may 
encounter unforeseen challenges not incorporated in the preliminary ex vivo studies 
conducted so far. Animal studies of renal cancer would be a suitable model to test the 
differences that might be expected in the human kidney in vivo. This research will likely 
also need to be pursued. 
6.3.Conclusions 
OCT is a non-invasive imaging technology that measures backscattered light 
intensity on the micrometer scale allowing it to perform an “optical biopsy” of biological 
tissue in real time at resolutions approaching that of conventional histopathology without 
the need for tissue excision and processing. OCT is readily interfaced with miniature 
imaging devices such as endoscopes, laparoscopes, catheters, needles, and other surgical 
probes to address the needs of a vast array of procedures in various medical fields. 
In conclusion, this research has demonstrated that OCT/DOCT can reveal 
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glomerular blood flow and renal microstructures in vivo and in real time. This was the 
first demonstration of 3D glomerular blood flow with OCT/DOCT technology. The 
tortuous and interwoven nature of the glomerular capillary bed was able to be visualized 
with 3D imaging. Glomerular blood flow was able to be quantified from 3D DOCT data 
volumes by measuring Doppler flow range (DFR) and cumulative Doppler volume 
(CDV) metrics. DOCT imaging detected changes in blood flow that were induced by 
administration of pharmacologic agents. Being able to quantify glomerular blood flow in 
vivo can be useful for studying renal disease progression, disease markers, and the effects 
of therapeutic interventions. 
Next, OCT/DOCT imaging of the kidney intra-operatively using a hand-held 
probe revealed kidney tubular morphology and blood flow in the superficial cortex of the 
transplanted kidney immediately following blood reperfusion in the recipient. This was 
the first demonstration of the feasibility for using OCT to image the human transplant 
kidney. This technique could be useful for intra-operative monitoring and evaluation of 
the transplanted kidney as a prognostic and diagnostic tool for patient-specific 
management strategies that can enable therapeutic interventions to be administered in a 
timely manner. We conclude that visualizing renal microstructures and blood flow in real 
time with OCT/DOCT is feasible, and therefore, it is a promising technique that may be 
able to predict post-graft renal function sooner than other currently available methods. 
Imaging results were compared with standard biomarkers of renal function to investigate 
if morphological and functional parameters derived from OCT imaging could predict 
post-graft outcome. However, we currently have too few patients to evaluate these 
parameters as a prognostic and diagnostic marker for post-transplant renal function. 
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Additional patient numbers are needed in order to establish a correlation. 
 Finally, we performed OCT imaging of ex vivo renal neoplasms using 
OCT and analyzed the attenuation coefficient for normal and tumor tissue. We conclude 
that using the attenuation coefficient from the OCT axial scan requires more investigation 
and in vivo pilot studies to draw a definitive conclusion on whether it can be a reliable 
indicator between normal and tumor renal tissue. Furthermore, as OCT spectroscopy and 
image analysis techniques continue to be developed, in addition to OCT contrast 
agents,
250
 OCT may be able to detect with greater accuracy and sensitivity pre-malignant 
neoplastic changes that would otherwise be undetectable in vivo with current technology. 
OCT has been shown to be a promising tool for diagnositics in many clinical 
areas, and as the performance and capability of OCT continues to improve, OCT will 
surely become a powerful imaging modality for the diagnosis and management of many 
diseases. As a relatively-new, clinical imaging modality, OCT imaging speed and 
portability can be improved in conjunction with laser technology and electronics. New 
OCT delivery devices can also be developed that give rise to new applications in the 
medical field that are yet unexplored. OCT can be readily interfaced fiber-optically with 
several existing diagnostic imaging modalities for integration with instruments currently 
available in the clinical suite. 
The utility of OCT in the clinic contains an unknown number of opportunities to 
be investigated. The work presented in this thesis on OCT/DOCT imaging of the kidney 
for studying renal diseases, for renal transplant diagnostics, and for renal cancer detection 
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